Oxidative stress and β-amyloid protein in Alzheimer's disease

NeuroMolecular Medicine

Volumn 13, Issue 4, 2011, Pages 223-250

  Cai, Zhiyou ^a,b   Zhao, Bin ^a   Ratka, Anna ^b  

^a GUANGDONG MEDICAL UNIVERSITY   (China)

^b TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

Author keywords

Alzheimer's disease; B Amyloid protein; Oxidative stress

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; BETA SECRETASE; CHEMOKINE; CLIOQUINOL; GAMMA SECRETASE; INTERLEUKIN 1; INTERLEUKIN 6; MATRIX METALLOPROTEINASE; MESSENGER RNA; REACTIVE OXYGEN METABOLITE; SECRETASE; TRICYCLO[4.3.0.1]DECAN 9 YL XANTHOGENATE; TUMOR NECROSIS FACTOR ALPHA;

ALZHEIMER DISEASE; AMYLOID PRECURSOR PROTEIN GENE; APOPTOSIS; ASTROCYTE; BLOOD BRAIN BARRIER; CELL ACTIVATION; CYTOKINE PRODUCTION; DEGENERATIVE DISEASE; DNA DAMAGE; DOWN REGULATION; ENZYME ACTIVATION; ENZYME ACTIVITY; EVIDENCE BASED MEDICINE; GENE; GENE EXPRESSION REGULATION; HUMAN; LIPID PEROXIDATION; MICROGLIA; NEUROPATHOLOGY; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; UPREGULATION;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; APOPTOSIS; BLOOD-BRAIN BARRIER; BRAIN; CYTOKINES; HUMANS; INFLAMMATION; MATRIX METALLOPROTEINASES; MICE; NEUROGLIA; OXIDATIVE STRESS; RATS;

EID: 84855866955     PISSN: 15351084     EISSN: 15591174     Source Type: Journal    
DOI: 10.1007/s12017-011-8155-9     Document Type: Review

References (411)

1. Aarli, J. A. (2003). Role of cytokines in neurological disorders. Current Medicinal Chemistry, 10, 1931-1937. (Pubitemid 37139055)
2. Abbott, N. J., Revest, P. A., & Romero, I. A. (1992). Astrocyte-endothelial interaction: Physiology and pathology. Neuropathology and Applied Neurobiology, 18, 424-433.
3. Abbott, N. J., Ronnback, L., & Hansson, E. (2006). Astrocyte-endothelial interactions at the blood-brain barrier. Nature Reviews. Neuroscience, 7, 41-53. (Pubitemid 41828930)
4. Abramov, A. Y., Canevari, L., & Duchen, M. R. (2004). Beta-amyloid peptides induce mitochondrial dysfunction and oxidative stress in astrocytes and death of neurons through activation of NADPH oxidase. Journal of Neuroscience, 24, 565-575. (Pubitemid 38112390)
5. Adlard, P. A., Cherny, R. A., Finkelstein, D. I., Gautier, E., Robb, E., Cortes, M., et al. (2008). Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta. Neuron, 59, 43-55. (Pubitemid 351905863)
6. Agid, Y. (1995). Aging, disease and nerve cell death. Bulletin de l'Académie Nationale de Médecine, 179, 1193-1203 (discussion 1197-1203).
7. Agostinho, P., Cunha, R. A., & Oliveira, C. (2010). Neuroinflammation, oxidative stress and the pathogenesis of Alzheimer's disease. Current Pharmaceutical Design, 16, 2766-2778.
8. Ait-Ghezala, G., Mathura, V. S., Laporte, V., Quadros, A., Paris, D., Patel, N., et al. (2005). Genomic regulation after CD40 stimulation in microglia: Relevance to Alzheimer's disease. Brain Research. Molecular Brain Research, 140, 73-85. (Pubitemid 41446149)
9. Akama, K. T., Albanese, C., Pestell, R. G., & Van Eldik, L. J. (1998). Amyloid beta-peptide stimulates nitric oxide production in astrocytes through an NFkappaB-dependent mechanism. Proceedings of the National Academy of Sciences of the United States of America, 95, 5795-5800. (Pubitemid 28224176)
10. Aksenov, M. Y., Aksenova, M. V., Carney, J. M., & Butterfield, D. A. (1997). Oxidative modification of glutamine synthetase by amyloid beta peptide. Free Radical Research, 27, 267-281. (Pubitemid 27474886)
11. Akterin, S., Cowburn, R. F., Miranda-Vizuete, A., Jimenez, A., Bogdanovic, N., Winblad, B., et al. (2006). Involvement of glutaredoxin-1 and thioredoxin-1 in beta-amyloid toxicity and Alzheimer's disease. Cell Death and Differentiation, 13, 1454-1465. (Pubitemid 44210349)
12. Alafuzoff, I., Adolfsson, R., Grundke-Iqbal, I., & Winblad, B. (1987). Blood-brain barrier in Alzheimer dementia and in non-demented elderly. An immunocytochemical study. Acta Neuropathologica, 73, 160-166. (Pubitemid 17060012)
13. 2+ dysregulation and neuronal death through activation of ionotropic glutamate receptors. Cell Calcium, 47, 264-272.
14. Alberghina, L., & Colangelo, A. M. (2006). The modular systems biology approach to investigate the control of apoptosis in Alzheimer's disease neurodegeneration. BMC Neuroscience, 7(Suppl 1), S2.
15. Alexiou, P., Chatzopoulou, M., Pegklidou, K., & Demopoulos, V. J. (2010). RAGE: A multi-ligand receptor unveiling novel insights in health and disease. Current Medicinal Chemistry, 17, 2232-2252.
16. Aliev, G. (2011). Oxidative stress induced-metabolic imbalance, mitochondrial failure, and cellular hypoperfusion as primary pathogenetic factors for the development of Alzheimer disease which can be used as a alternate and successful drug treatment strategy: Past, present and future. CNS & Neurological Disorders Drug Targets, 10, 147-148.
17. Allan, S. M., Harrison, D. C., Read, S., Collins, B., Parsons, A. A., Philpott, K., et al. (2001). Selective increases incytokine expression in the rat brain in response to striatal injection of alpha-amino-3-hydroxy-5-methyl-4- isoxazolepropionate and interleukin-1. Brain Research. Molecular Brain Research, 93, 180-189. (Pubitemid 32925178)
18. Allen, C. L., & Bayraktutan, U. (2009a). Antioxidants attenuate hyperglycaemia-mediated brain endothelial cell dysfunction and blood-brain barrier hyperpermeability. Diabetes, Obesity & Metabolism, 11, 480-490.
19. Allen, C. L., & Bayraktutan, U. (2009b). Oxidative stress and its role in the pathogenesis of ischaemic stroke. International Journal of Stroke, 4, 461-470.
20. Aluise, C. D., Robinson, R. A., Beckett, T. L., Murphy, M. P., Cai, J., Pierce, W. M., et al. (2010). Preclinical Alzheimer disease: Brain oxidative stress, Abeta peptide and proteomics. Neurobiology of Diseases, 39, 221-228.
21. Anderson, I., Adinolfi, C., Doctrow, S., Huffman, K., Joy, K. A., Malfroy, B., et al. (2001). Oxidative signalling and inflammatory pathways in Alzheimer's disease. Biochemical Society Symposium, 67, 141-149. (Pubitemid 33602682)
22. Ansari, M. A., Joshi, G., Huang, Q., Opii, W. O., Abdul, H. M., Sultana, R., et al. (2006). In vivo administration of D609 leads to protection of subsequently isolated gerbil brain mitochondria subjected to in vitro oxidative stress induced by amyloid beta-peptide and other oxidative stressors: Relevance to Alzheimer's disease and other oxidative stress-related neurodegenerative disorders. Free Radical Biology and Medicine, 41, 1694-1703. (Pubitemid 44634240)
23. Ansari, M. A., & Scheff, S. W. (2010). Oxidative stress in the progression of Alzheimer disease in the frontal cortex. Journal of Neuropathology and Experimental Neurology, 69, 155-167.
24. Apelt, J., Bigl, M., Wunderlich, P., & Schliebs, R. (2004). Agingrelated increase in oxidative stress correlates with developmental pattern of beta-secretase activity and beta-amyloid plaque formation in transgenic Tg2576 mice with Alzheimer-like pathology. International Journal of Developmental Neuroscience, 22, 475-484. (Pubitemid 39311436)
25. Apelt, J., & Schliebs, R. (2001). Beta-amyloid-induced glial expression of both pro- and anti-inflammatory cytokines in cerebral cortex of aged transgenic Tg2576 mice with Alzheimer plaque pathology. Brain Research, 894, 21-30. (Pubitemid 32197594)
26. Armulik, A., Genove, G., Mae, M., Nisancioglu, M. H., Wallgard, E., Niaudet, C., et al. (2010). Pericytes regulate the blood-brain barrier. Nature, 468, 557-561.
27. Aukrust, P., Berge, R. K., Ueland, T., Aaser, E., Damas, J. K., Wikeby, L., et al. (2001). Interaction between chemokines and oxidative stress: Possible pathogenic role in acute coronary syndromes. Journal of the American College of Cardiology, 37, 485-491.
28. Ayasolla, K., Khan, M., Singh, A. K., & Singh, I. (2004). Inflammatory mediator and beta-amyloid (25-35)-induced ceramide generation and iNOS expression are inhibited by vitamin E. Free Radical Biology and Medicine, 37, 325-338. (Pubitemid 38833999)
29. Bachmeier, C., Mullan, M., & Paris, D. (2010). Characterization and use of human brain microvascular endothelial cells to examine beta-amyloid exchange in the blood-brain barrier. Cytotechnology, 62, 519-529.
30. Backstrom, J. R., Lim, G. P., Cullen, M. J., & Tokes, Z. A. (1996). Matrix metalloproteinase-9 (MMP-9) is synthesized in neurons of the human hippocampus and is capable of degrading the amyloid-beta peptide (1-40). Journal of Neuroscience, 16, 7910-7919. (Pubitemid 26405054)
31. Bacon, K. B., & Harrison, J. K. (2000). Chemokines and their receptors in neurobiology: Perspectives in physiology and homeostasis. Journal of Neuroimmunology, 104, 92-97. (Pubitemid 30100542)
32. Bader Lange, M. L., Cenini, G., Piroddi, M., Abdul, H. M., Sultana, R., Galli, F., et al. (2008). Loss of phospholipid asymmetry and elevated brain apoptotic protein levels in subjects with amnestic mild cognitive impairment and Alzheimer disease. Neurobiology of Diseases, 29, 456-464.
33. Bader Lange, M. L., St. Clair, D., Markesbery, W. R., Studzinski, C. M., Murphy, M. P., & Butterfield, D. A. (2010). Age-related loss of phospholipid asymmetry in APP(NLh)/APP(NLh) 9 PS-1(P264L)/PS-1(P264L) human double mutant knock-in mice: Relevance to Alzheimer disease. Neurobiology of Diseases, 38, 104-115.
34. Bading, J. R., Yamada, S., Mackic, J. B., Kirkman, L., Miller, C., Calero, M., et al. (2002). Brain clearance of Alzheimer's amyloid-beta40 in the squirrel monkey: A SPECT study in a primate model of cerebral amyloid angiopathy. Journal of Drug Targeting, 10, 359-368. (Pubitemid 34746318)
35. Bajetto, A., Bonavia, R., Barbero, S., Florio, T., & Schettini, G. (2001). Chemokines and their receptors in the central nervous system. Frontiers in Neuroendocrinology, 22, 147-184. (Pubitemid 32706335)
36. Baker, P. R., Schopfer, F. J., O'Donnell, V. B., & Freeman, B. A. (2009). Convergence of nitric oxide and lipid signaling: Antiinflammatory nitro-fatty acids. Free Radical Biology and Medicine, 46, 989-1003.
37. Bakshi, P., Margenthaler, E., Laporte, V., Crawford, F., & Mullan, M. (2008). Novel role of CXCR2 in regulation of gamma-secretase activity. ACS Chemical Biology, 3, 777-789.
38. Bakshi, P., Margenthaler, E., Reed, J., Crawford, F., & Mullan, M. (2011). Depletion of CXCR2 inhibits gamma-secretase activity and amyloid-beta production in a murine model of Alzheimer's disease. Cytokine, 53, 163-169.
39. Baranowska-Bik, A., Bik, W., Wolinska-Witort, E., Martynska, L., Chmielowska, M., Barcikowska, M., et al. (2008). Plasma beta amyloid and cytokine profile in women with Alzheimer's disease. Neuro Endocrinology Letters, 29, 75-79.
40. Barger, S. W., Smith-Swintosky, V. L., Rydel, R. E., & Mattson, M. P. (1993). Beta-amyloid precursor protein mismetabolism and loss of calcium homeostasis in Alzheimer's disease. Annals of the New York Academy of Sciences, 695, 158-164. (Pubitemid 23348254)
41. Barten, D. M., & Albright, C. F. (2008). Therapeutic strategies for Alzheimer's disease. Molecular Neurobiology, 37, 171-186.
42. Baskin, F., Rosenberg, R. N., & Davis, R. M. (1992). Morphological differentiation and proteoglycan synthesis regulate Alzheimer amyloid precursor protein processing in PC-12 and human astrocyte cultures. Journal of Neuroscience Research, 32, 274-279.
43. Basu, A., Castle, V. P., Bouziane, M., Bhalla, K., & Haldar, S. (2006). Crosstalk between extrinsic and intrinsic cell death pathways in pancreatic cancer: Synergistic action of estrogen metabolite and ligands of death receptor family. Cancer Research, 66, 4309-4318.
44. Battaini, F., Pascale, A., Lucchi, L., Pasinetti, G. M., & Govoni, S. (1999). Protein kinase C anchoring deficit in postmortem brains of Alzheimer's disease patients. Experimental Neurology, 159, 559-564. (Pubitemid 29485243)
45. Bayer, T. A., Schafer, S., Breyhan, H., Wirths, O., Treiber, C., & Multhaup, G. (2006). A vicious circle: Role of oxidative stress, intraneuronal Abeta and Cu in Alzheimer's disease. Clinical Neuropathology, 25, 163-171. (Pubitemid 44047901)
46. Behl, C., & Moosmann, B. (2002). Oxidative nerve cell death in Alzheimer's disease and stroke: Antioxidants as neuroprotective compounds. Biological Chemistry, 383, 521-536. (Pubitemid 34506288)
47. Bell, R. D., & Zlokovic, B. V. (2009). Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer's disease. Acta Neuropathologica, 118, 103-113.
48. Bergamini, C. M., Gambetti, S., Dondi, A., & Cervellati, C. (2004). Oxygen, reactive oxygen species and tissue damage. Current Pharmaceutical Design, 10, 1611-1626. (Pubitemid 38559774)
49. Bernhard, D., & Wang, X. L. (2007). Smoking, oxidative stress and cardiovascular diseases - do anti-oxidative therapies fail? Current Medicinal Chemistry, 14, 1703-1712. (Pubitemid 47163408)
50. Bezprozvanny, I., & Mattson, M. P. (2008). Neuronal calcium mishandling and the pathogenesis of Alzheimer's disease. Trends in Neurosciences, 31, 454-463.
51. Blasig, I. E., Mertsch, K., & Haseloff, R. F. (2002). Nitronyl nitroxides, a novel group of protective agents against oxidative stress in endothelial cells forming the blood-brain barrier. Neuropharmacology, 43, 1006-1014. (Pubitemid 35341236)
52. Blass, J. P., & Gibson, G. E. (1991). The role of oxidative abnormalities in the pathophysiology of Alzheimer's disease. Revue Neurologique (Paris), 147, 513-525.
53. Blume, A. J., & Vitek, M. P. (1989). Focusing on IL-1-promotion of beta-amyloid precursor protein synthesis as an early event in Alzheimer's disease. Neurobiology of Aging, 10, 406-408 (discussion 404-412). (Pubitemid 19245428)
54. Bonda, D. J., Wang, X., Perry, G., Nunomura, A., Tabaton, M., Zhu, X., et al. (2010). Oxidative stress in Alzheimer disease: A possibility for prevention. Neuropharmacology, 59, 290-294.
55. Bonifati, D. M., & Kishore, U. (2007). Role of complement in neurodegeneration and neuroinflammation. Molecular Immunology, 44, 999-1010. (Pubitemid 44414994)
56. Bosco, D., Fava, A., Plastino, M., Montalcini, T., & A. Pujia. (2011). Possible implications of insulin resistance and glucose metabolism in Alzheimer's disease pathogenesis. Journal of Cellular and Molecular Medicine.
57. Bossu, P., Ciaramella, A., Moro, M. L., Bellincampi, L., Bernardini, S., Federici, G., et al. (2007). Interleukin 18 gene polymorphisms predict risk and outcome of Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry, 78, 807-811. (Pubitemid 47204582)
58. Boulanger, E., Wautier, J. L., Dequiedt, P., & Schmidt, A. M. (2006). Glycation, glycoxidation and diabetes mellitus. Néphrologie & Thérapeutique, 2(Suppl 1), S8-S16. (Pubitemid 43156001)
59. Bourne, K. Z., Ferrari, D. C., Lange-Dohna, C., Rossner, S., Wood, T. G., & Perez-Polo, J. R. (2007). Differential regulation of BACE1 promoter activity by nuclear factor-kappaB in neurons and glia upon exposure to beta-amyloid peptides. Journal of Neuroscience Research, 85, 1194-1204. (Pubitemid 46724363)
60. Boyd-Kimball, D., Poon, H. F., Lynn, B. C., Cai, J., Pierce, W. M., Jr., Klein, J. B., et al. (2006). Proteomic identification of proteins specifically oxidized in Caenorhabditis elegans expressing human Abeta(1-42): Implications for Alzheimer's disease. Neurobiology of Aging, 27, 1239-1249. (Pubitemid 44067304)
61. Bradt, B. M., Kolb, W. P., & Cooper, N. R. (1998). Complement-dependent proinflammatory properties of the Alzheimer's disease beta-peptide. Journal of Experimental Medicine, 188, 431-438. (Pubitemid 28369133)
62. Buchhave, P., Zetterberg, H., Blennow, K., Minthon, L., Janciauskiene, S., & Hansson, O. (2010). Soluble TNF receptors are associated with Abeta metabolism and conversion to dementia in subjects with mild cognitive impairment. Neurobiology of Aging, 31, 1877-1884.
63. Buoso, E., Lanni, C., Schettini, G., Govoni, S., & Racchi, M. (2010). Beta-amyloid precursor protein metabolism: Focus on the functions and degradation of its intracellular domain. Pharmacological Research, 62, 308-317.
64. Bush, A. I. (2002). Metal complexing agents as therapies for Alzheimer's disease. Neurobiology of Aging, 23, 1031-1038. (Pubitemid 35447784)
65. Butterfield, D. A., & Boyd-Kimball, D. (2004). Amyloid beta-peptide(1-42) contributes to the oxidative stress and neurode-generation found in Alzheimer disease brain. Brain Pathology, 14, 426-432. (Pubitemid 39524972)
66. Butterfield, D. A., Galvan, V., Lange, M. B., Tang, H., Sowell, R. A., Spilman, P., et al. (2010a). In vivo oxidative stress in brain of Alzheimer disease transgenic mice: Requirement for methionine 35 in amyloid beta-peptide of APP. Free Radical Biology and Medicine, 48, 136-144.
67. Butterfield, D. A., Griffin, S., Munch, G., & Pasinetti, G. M. (2002). Amyloid beta-peptide and amyloid pathology are central to the oxidative stress and inflammatory cascades under which Alzheimer's disease brain exists. Journal of Alzheimer's Disease, 4, 193-201. (Pubitemid 35006051)
68. Butterfield, D. A., Hardas, S. S., & Lange, M. L. (2010b). Oxidatively modified glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and Alzheimer's disease: Many pathways to neurodegeneration. Journal of Alzheimer's Disease, 20, 369-393.
69. Butterfield, D. A., & Lauderback, C. M. (2002). Lipid peroxidation and protein oxidation in Alzheimer's disease brain: Potential causes and consequences involving amyloid beta-peptide-associated free radical oxidative stress. Free Radical Biology and Medicine, 32, 1050-1060. (Pubitemid 34603342)
70. Butterfield, D. A., & Pocernich, C. B. (2003). The glutamatergic system and Alzheimer's disease: Therapeutic implications. CNS Drugs, 17, 641-652. (Pubitemid 36920542)
71. Butterfield, D. A., Reed, T., Newman, S. F., & Sultana, R. (2007). Roles of amyloid beta-peptide-associated oxidative stress and brain protein modifications in the pathogenesis of Alzheimer's disease and mild cognitive impairment. Free Radical Biology and Medicine, 43, 658-677. (Pubitemid 47102132)
72. Cabello-Verrugio, C., & Brandan, E. (2007). A novel modulatory mechanism of transforming growth factor-beta signaling through decorin and LRP-1. The Journal of Biological Chemistry, 282, 18842-18850. (Pubitemid 47100183)
73. Calingasan, N. Y., Baker, H., Sheu, K. F., & Gibson, G. E. (1995). Blood-brain barrier abnormalities in vulnerable brain regions during thiamine deficiency. Experimental Neurology, 134, 64-72.
74. Camins, A., Pallas, M., & Silvestre, J. S. (2008). Apoptotic mechanisms involved in neurodegenerative diseases: Experimental and therapeutic approaches. Methods and Findings in Experimental and Clinical Pharmacology, 30, 43-65. (Pubitemid 351397455)
75. Campos, S. P., Wang, Y., Koj, A., & Baumann, H. (1993). Divergent transforming growth factor-beta effects on IL-6 regulation of acute phase plasma proteins in rat hepatoma cells. Journal of Immunology, 151, 7128-7137. (Pubitemid 24001087)
76. Candelario-Jalil, E., Thompson, J., Taheri, S., Grossetete, M., Adair, J. C., Edmonds, E., et al. (2011). Matrix metalloproteinases are associated with increased blood-brain barrier opening in vascular cognitive impairment. Stroke, 42, 1345-1350.
77. Candore, G., Bulati, M., Caruso, C., Castiglia, L., Colonna-Romano, G., Di Bona, D., et al. (2010). Inflammation, cytokines, immune response, apolipoprotein E, cholesterol, and oxidative stress in Alzheimer disease: Therapeutic implications. Rejuvenation Research, 13, 301-313.
78. Carrano, A., Hoozemans, J. J., van der Vies, S. M., Rozemuller, A. J., van Horssen, J., & H. E. de Vries. (2011). Amyloid beta induces oxidative stress-mediated blood-brain barrier changes in capillary amyloid angiopathy. Antioxidants & Redox Signaling, 15, 1167-1178.
79. Carta, M. G., Serra, P., Ghiani, A., Manca, E., Hardoy, M. C., Del Giacco, G. S., et al. (2002). Chemokines and pro-inflammatory cytokines in Down's syndrome: An early marker for Alzheimertype dementia? Psychotherapy and Psychosomatics, 71, 233-236. (Pubitemid 34830399)
80. Cechetto, D. F. (2001). Role of nuclear factor kappa B in neuropathological mechanisms. Progress in Brain Research, 132, 391-404.
81. Cenini, G., Sultana, R., Memo, M., & Butterfield, D. A. (2008a). Effects of oxidative and nitrosative stress in brain on p53 proapoptotic protein in amnestic mild cognitive impairment and Alzheimer disease. Free Radical Biology and Medicine, 45, 81-85.
82. Cenini, G., Sultana, R., Memo, M., & Butterfield, D. A. (2008b). Elevated levels of pro-apoptotic p53 and its oxidative modification by the lipid peroxidation product, HNE, in brain from subjects with amnestic mild cognitive impairment and Alzheimer's disease. Journal of Cellular and Molecular Medicine, 12, 987-994. (Pubitemid 351718076)
83. Chan, A., & Shea, T. B. (2007). Folate deprivation increases presenilin expression, gamma-secretase activity, and Abeta levels in murine brain: potentiation by ApoE deficiency and alleviation by dietary S-adenosyl methionine. Journal of Neurochemistry, 102, 753-760. (Pubitemid 47057297)
84. Chang, S., ran Ma, T., Miranda, R. D., Balestra, M. E., Mahley, R. W., & Huang, Y. (2005). Lipid- and receptor-binding regions of apolipoprotein E4 fragments act in concert to cause mitochon-drial dysfunction and neurotoxicity. Proceedings of the National Academy of Sciences of the United States of America, 102, 18694-18699. (Pubitemid 43011288)
85. Chen, L., Na, R., Gu, M., Richardson, A., & Ran, Q. (2008). Lipid peroxidation up-regulates BACE1 expression in vivo: a possible early event of amyloidogenesis in Alzheimer's disease. Journal of Neurochemistry, 107, 197-207.
86. Chen, X., Walker, D. G., Schmidt, A. M., Arancio, O., Lue, L. F., & Yan, S. D. (2007). RAGE: A potential target for Abeta-mediated cellular perturbation in Alzheimer's disease. Current Molecular Medicine, 7, 735-742.
87. Chen, C. H., Zhou, W., Liu, S., Deng, Y., Cai, F., Tone, M., et al. (2011). Increased NF-kappaB signalling up-regulates BACE1 expression and its therapeutic potential in Alzheimer's disease. The International Journal of Neuropsychopharmacology, 18, 1-14.
88. Cherny, R. A., Legg, J. T., McLean, C. A., Fairlie, D. P., Huang, X., Atwood, C. S., et al. (1999). Aqueous dissolution of Alzheimer's disease Abeta amyloid deposits by biometal depletion. The Journal of Biological Chemistry, 274, 23223-23228.
89. Choe, W., Stoica, G., Lynn, W., & Wong, P. K. (1998). Neurodegeneration induced by MoMuLV-ts1 and increased expression of Fas and TNF-alpha in the central nervous system. Brain Research, 779, 1-8. (Pubitemid 28039933)
90. Chong, Y. H., Shin, S. A., Lee, H. J., Kang, J. H., & Suh, Y. H. (2002). Molecular mechanisms underlying cyclic AMP inhibition of macrophage dependent TNF-alpha production and neurotoxicity in response to amyloidogenic C-terminal fragment of Alzheimer's amyloid precursor protein. Journal of Neuroimmunology, 133, 160-174. (Pubitemid 35346738)
91. Christen, Y. (2000). Oxidative stress and Alzheimer disease. American Journal of Clinical Nutrition, 71, 621S-629S. (Pubitemid 30061247)
92. Cirrito, J. R., Deane, R., Fagan, A. M., Spinner, M. L., Parsadanian, M., Finn, M. B., et al. (2005). P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model. Journal of Clinical Investigation, 115, 3285-3290. (Pubitemid 41567593)
93. Cole, S. L., & Vassar, R. (2008). The role of amyloid precursor protein processing by BACE1, the beta-secretase, in Alzheimer disease pathophysiology. The Journal of Biological Chemistry, 283, 29621-29625.
94. Combarros, O., van Duijn, C. M., Hammond, N., Belbin, O., Arias-Vasquez, A., Cortina-Borja, M., et al. (2009). Replication by the Epistasis Project of the interaction between the genes for IL-6 and IL-10 in the risk of Alzheimer's disease. Journal of Neuroinflammation, 6, 22.
95. Combs, C. K., Johnson, D. E., Karlo, J. C., Cannady, S. B., & Landreth, G. E. (2000). Inflammatory mechanisms in Alzheimer's disease: inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists. Journal of Neuroscience, 20, 558-567. (Pubitemid 30225558)
96. Combs, C. K., Karlo, J. C., Kao, S. C., & Landreth, G. E. (2001). Beta-amyloid stimulation of microglia and monocytes results in TNFalpha-dependent expression of inducible nitric oxide synthase and neuronal apoptosis. Journal of Neuroscience, 21, 1179-1188. (Pubitemid 32128763)
97. Conway, E. L., Gundlach, A. L., & Craven, J. A. (1998). Temporal changes in glial fibrillary acidic protein messenger RNA and [3H]PK11195 binding in relation to imidazoline-I2-receptor and alpha 2-adrenoceptor binding in the hippocampus following transient global forebrain ischaemia in the rat. Neuroscience, 82, 805-817. (Pubitemid 27479619)
98. Cotman, C. W. (1998). Apoptosis decision cascades and neuronal degeneration in Alzheimer's disease. Neurobiology of Aging, 19, S29-S32. (Pubitemid 28178934)
99. Cruz-Sanchez, F. F., Girones, X., Ortega, A., Alameda, F., & Lafuente, J. V. (2010). Oxidative stress in Alzheimer's disease hippocampus: A topographical study. Journal of the Neurological Sciences, 299, 163-167.
100. Cui, J. G., Li, Y. Y., Zhao, Y., Bhattacharjee, S., & Lukiw, W. J. (2010). Differential regulation of interleukin-1 receptor-associated kinase-1 (IRAK-1) and IRAK-2 by microRNA-146a and NF-kappaB in stressed human astroglial cells and in Alzheimer disease. The Journal of Biological Chemistry, 285, 38951-38960.
101. Cuschieri, J., & Maier, R. V. (2007). Oxidative stress, lipid rafts, and macrophage reprogramming. Antioxidants & Redox Signaling, 9, 1485-1497. (Pubitemid 47260438)
102. Cuvelier, A., Kuntz, C., Sesboue, R., Muir, J. F., & Martin, J. P. (1997). Metalloproteinases in the extracellular matrix: Structure and activity. Revue des Maladies Respiratoires, 14, 1-10. (Pubitemid 27104046)
103. Dal Pra, I., Chiarini, A., Pacchiana, R., Chakravarthy, B., Whitfield, J. F., & Armato, U. (2008). Emerging concepts of how beta-amyloid proteins and pro-inflammatory cytokines might collaborate to produce an 'Alzheimer brain' (review). Molecular Medicine Reports, 1, 173-178.
104. De Felice, F.G., Velasco, P. T., Lambert, M.P., Viola, K., Fernandez, S. J., Ferreira, S. T., et al. (2007). Abeta oligomers induce neuronal oxidative stress through an N-methyl-D-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine. The Journal of Biological Chemistry, 282, 11590-11601. (Pubitemid 47100810)
105. de la Monte, S. M., Luong, T., Neely, T. R., Robinson, D., & Wands, J. R. (2000). Mitochondrial DNA damage as a mechanism of cell loss in Alzheimer's disease. Laboratory Investigation, 80, 1323-1335. (Pubitemid 30637072)
106. de la Torre, J. C., & Mussivand, T. (1993). Can disturbed brain microcirculation cause Alzheimer's disease? Neurological Research, 15, 146-153. (Pubitemid 23166998)
107. Deane, R., Bell, R. D., Sagare, A., & Zlokovic, B. V. (2009). Clearance of amyloid-beta peptide across the blood-brain barrier: Implication for therapies in Alzheimer's disease. CNS & Neurological Disorders Drug Targets, 8, 16-30.
108. Deane, R., Du Yan, S., Submamaryan, R. K., LaRue, B., Jovanovic, S., Hogg, E., et al. (2003). RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nature Medicine, 9, 907-913. (Pubitemid 36889934)
109. Deane, R., Sagare, A., Hamm, K., Parisi, M., Lane, S., Finn, M. B., et al. (2008a). apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. Journal of Clinical Investigation, 118, 4002-4013.
110. Deane, R., Sagare, A., & Zlokovic, B. V. (2008b). The role of the cell surface LRP and soluble LRP in blood-brain barrier Abeta clearance in Alzheimer's disease. Current Pharmaceutical Design, 14, 1601-1605. (Pubitemid 352002987)
111. Deane, R., Wu, Z., & Zlokovic, B. V. (2004). RAGE (yin) versus LRP (yang) balance regulates alzheimer amyloid beta-peptide clearance through transport across the blood-brain barrier. Stroke, 35, 2628-2631. (Pubitemid 39458354)
112. Deigner, H. P., Haberkorn, U., & Kinscherf, R. (2000). Apoptosis modulators in the therapy of neurodegenerative diseases. Expert Opinion on Investigational Drugs, 9, 747-764. (Pubitemid 30175643)
113. Del Bo, R., Angeretti, N., Lucca, E., De Simoni, M. G., & Forloni, G. (1995). Reciprocal control of inflammatory cytokines, IL-1 and IL-6, and beta-amyloid production in cultures. Neuroscience Letters, 188, 70-74.
114. Del Villar, K., & Miller, C. A. (2004). Down-regulation of DENN/MADD, a TNF receptor binding protein, correlates with neuronal cell death in Alzheimer's disease brain and hippocampal neurons. Proceedings of the National Academy of Sciences of the United States of America, 101, 4210-4215. (Pubitemid 38405908)
115. del Zoppo, G. J., & Milner, R. (2006). Integrin-matrix interactions in the cerebral microvasculature. Arteriosclerosis, Thrombosis, and Vascular Biology, 26, 1966-1975. (Pubitemid 44253776)
116. Del Zoppo, G. J., Milner, R., Mabuchi, T., Hung, S., Wang, X., & Koziol, J. A. (2006). Vascular matrix adhesion and the bloodbrain barrier. Biochemical Society Transactions, 34, 1261-1266. (Pubitemid 46769034)
117. Dickson, D. W., Lee, S. C., Mattiace, L. A., Yen, S. H., & Brosnan, C. (1993). Microglia and cytokines in neurological disease, with special reference to AIDS and Alzheimer's disease. Glia, 7, 75-83.
118. Dinarello, C. A. (2000). Proinflammatory cytokines. Chest, 118, 503-508. (Pubitemid 30637822)
119. Donahue, J. E., Flaherty, S. L., Johanson, C. E., Duncan, J. A., III, Silverberg, G. D., Miller, M. C., et al. (2006). RAGE, LRP-1, and amyloid-beta protein in Alzheimer's disease. Acta Neuropathologica, 112, 405-415. (Pubitemid 44469161)
120. Donahue, J. E., & Johanson, C. E. (2008). Apolipoprotein E, amyloid-beta, and blood-brain barrier permeability in Alzheimer disease. Journal of Neuropathology and Experimental Neurology, 67, 261-270. (Pubitemid 351507482)
121. Donnelly, R. J., Friedhoff, A. J., Beer, B., Blume, A. J., & Vitek, M. P. (1990). Interleukin-1 stimulates the beta-amyloid precursor protein promoter. Cellular and Molecular Neurobiology, 10, 485-495.
122. Du, Y., Wooten, M. C., Gearing, M., & Wooten, M. W. (2009). Ageassociated oxidative damage to the p62 promoter: Implications for Alzheimer disease. Free Radical Biology and Medicine, 46, 492-501.
123. Dumont, M., & Beal, M. F. (2010). Neuroprotective strategies involving ROS in Alzheimer disease. Free Radical Biology & Medicine, 51, 1014-1026.
124. Duyckaerts, C., Delatour, B., & Potier, M. C. (2009). Classification and basic pathology of Alzheimer disease. Acta Neuropathologica, 118, 5-36.
125. El Khoury, J. B., Moore, K. J., Means, T. K., Leung, J., Terada, K., Toft, M., et al. (2003). CD36 mediates the innate host response to beta-amyloid. Journal of Experimental Medicine, 197, 1657-1666. (Pubitemid 36745341)
126. Eliceiri, B. P., Gonzalez, A. M., & Baird, A. (2011). Zebrafish model of the blood-brain barrier: Morphological and permeability studies. Methods in Molecular Biology, 686, 371-378.
127. Elmore, S. (2007). Apoptosis: A review of programmed cell death. Toxicologic Pathology, 35, 495-516. (Pubitemid 46911891)
128. Fang, F., Lue, L. F., Yan, S., Xu, H., Luddy, J. S., Chen, D., et al. (2010). RAGE-dependent signaling in microglia contributes to neuroinflammation, Abeta accumulation, and impaired learning/memory in a mouse model of Alzheimer's disease. FASEB J, 24, 1043-1055.
129. Fedorov, V. P., Ushakov, I. B., Kordenko, A. N., Drobyshev, V. I., & Davydov, B. I. (1989). Structuro-functional organization of the blood-brain barrier. Izvestiia Akademii Nauk. Seriia biologicheskaia, Jan-Feb(1), 24-34.
130. Feghali, C. A., & Wright, T. M. (1997). Cytokines in acute and chronic inflammation. Frontiers in Bioscience, 2, d12-d26.
131. Fenoglio, C., Galimberti, D., Lovati, C., Guidi, I., Gatti, A., Fogliarino, S., et al. (2004). MCP-1 in Alzheimer's disease patients: A-2518G polymorphism and serum levels. Neurobiology of Aging, 25, 1169-1173. (Pubitemid 39094019)
132. Fiala, M., & Veerhuis, R. (2010). Biomarkers of inflammation and amyloid-beta phagocytosis in patients at risk of Alzheimer disease. Experimental Gerontology, 45, 57-63.
133. Filiz, G., Price, K. A., Caragounis, A., Du, T., Crouch, P. J., & White, A. R. (2008). The role of metals in modulating metalloprotease activity in the AD brain. European Biophysics Journal, 37, 315-321.
134. Fillit, H., Ding, W. H., Buee, L., Kalman, J., Altstiel, L., Lawlor, B., et al. (1991). Elevated circulating tumor necrosis factor levels in Alzheimer's disease. Neuroscience Letters, 129, 318-320.
135. Finder, V. H. (2010). Alzheimer's disease: A general introduction and pathomechanism. Journal of Alzheimer's Disease, 22(Suppl 3), 5-19.
136. Flex, A., Gaetani, E., Proia, A. S., Pecorini, G., Straface, G., Biscetti, F., et al. (2006). Analysis of functional polymorphisms of metalloproteinase genes in persons with vascular dementia and Alzheimer's disease. Journals of Gerontology. Series A, Biological Sciences and Medical Sciences, 61, 1065-1069. (Pubitemid 44727215)
137. Forman, H. J., Fukuto, J. M., & Torres, M. (2004). Redox signaling: Thiol chemistry defines which reactive oxygen and nitrogen species can act as second messengers. American Journal of Physiology, 287, C246-C256. (Pubitemid 38955213)
138. Frackowiak, J., Zoltowska, A., & Wisniewski, H. M. (1994). Non-fibrillar beta-amyloid protein is associated with smooth muscle cells of vessel walls in Alzheimer disease. Journal of Neuropathology and Experimental Neurology, 53, 637-645.
139. Fujita, S., Seino, K., Sato, K., Sato, Y., Eizumi, K., Yamashita, N., et al. (2006). Regulatory dendritic cells act as regulators of acute lethal systemic inflammatory response. Blood, 107, 3656-3664.
140. Fuller, S., Steele, M., & Munch, G. (2010). Activated astroglia during chronic inflammation in Alzheimer's disease - do they neglect their neurosupportive roles? Mutation Research, 690, 40-49.
141. Galasko, D., & Montine, T. J. (2010). Biomarkers of oxidative damage and inflammation in Alzheimer's disease. Biomarkers in Medicine, 4, 27-36.
142. Garcia-Matas, S., de Vera, N., Aznar, A. O., Marimon, J. M., Adell, A., Planas, A. M., et al. (2010). In vitro and in vivo activation of astrocytes by amyloid-beta is potentiated by pro-oxidant agents. Journal of Alzheimer's Disease, 20, 229-245.
143. Garcia-Ospina, G. P., Jimenez-Del Rio, M., Lopera, F., & Velez-Pardo, C. (2003). Neuronal DNA damage correlates with a positive detection of c-Jun, nuclear factor kB, p53 and Par-4 transcription factors in Alzheimer's disease. Revista de Neurologia, 36, 1004-1010. (Pubitemid 36899381)
144. Garrido, N., Meseguer, M., Simon, C., Pellicer, A., & Remohi, J. (2004). Pro-oxidative and anti-oxidative imbalance in human semen and its relation with male fertility. Asian Journal of Andrology, 6, 59-65. (Pubitemid 38418340)
145. Gasche, Y., Copin, J. C., Sugawara, T., Fujimura, M., & Chan, P. H. (2001). Matrix metalloproteinase inhibition prevents oxidative stress-associated blood-brain barrier disruption after transient focal cerebral ischemia. Journal of Cerebral Blood Flow and Metabolism, 21, 1393-1400. (Pubitemid 33120943)
146. Gasic-Milenkovic, J., Loske, C., & Munch, G. (2003). Advanced glycation endproducts cause lipid peroxidation in the human neuronal cell line SH-SY5Y. Journal of Alzheimer's Disease, 5, 25-30. (Pubitemid 36422848)
147. Ge, Y. W., & Lahiri, D. K. (2002). Regulation of promoter activity of the APP gene by cytokines and growth factors: Implications in Alzheimer's disease. Annals of the New York Academy of Sciences, 973, 463-467. (Pubitemid 36125054)
148. Gella, A., & Durany, N. (2009). Oxidative stress in Alzheimer disease. Cell Adhesion & Migration, 3, 88-93.
149. Ghiso, J., Tomidokoro, Y., Revesz, T., Frangione, B., & Rostagno, A. (2010). Cerebral amyloid angiopathy and Alzheimer's disease. Hirosaki Igaku, 61, S111-S124.
150. Ghribi, O., Golovko, M. Y., Larsen, B., Schrag, M., & Murphy, E. J. (2006). Deposition of iron and beta-amyloid plaques is associated with cortical cellular damage in rabbits fed with long-term cholesterol-enriched diets. Journal of Neurochemistry, 99, 438-449. (Pubitemid 44477201)
151. Giardino, I., Edelstein, D., & Brownlee, M. (1996). BCL-2 expression or antioxidants prevent hyperglycemia-induced formation of intracellular advanced glycation endproducts in bovine endothelial cells. Journal of Clinical Investigation, 97, 1422-1428. (Pubitemid 26097031)
152. Gibson, G. E., Park, L. C., Zhang, H., Sorbi, S., & Calingasan, N. Y. (1999). Oxidative stress and a key metabolic enzyme in Alzheimer brains, cultured cells, and an animal model of chronic oxidative deficits. Annals of the New York Academy of Sciences, 893, 79-94. (Pubitemid 30038069)
153. Gilgun-Sherki, Y., Melamed, E., & Offen, D. (2001). Oxidative stress induced-neurodegenerative diseases: The need for antioxidants that penetrate the blood brain barrier. Neuropharmacology, 40, 959-975. (Pubitemid 32530602)
154. Gilgun-Sherki, Y., Melamed, E., & Offen, D. (2003). Antioxidant treatment in Alzheimer's disease: Current state. Journal of Molecular Neuroscience, 21, 1-11. (Pubitemid 37204866)
155. Glinsky, G. V., & Glinsky, V. V. (1996). Apoptosis and metastasis: A superior resistance of metastatic cancer cells to programmed cell death. Cancer Letters, 101, 43-51. (Pubitemid 26060191)
156. Golde, T. E. (2002). Inflammation takes on Alzheimer disease. Nature Medicine, 8, 936-938. (Pubitemid 35033689)
157. Goldgaber, D., Harris, H. W., Hla, T., Maciag, T., Donnelly, R. J., Jacobsen, J. S., et al. (1989). Interleukin 1 regulates synthesis of amyloid beta-protein precursor mRNA in human endothelial cells. Proceedings of the National Academy of Sciences of the United States of America, 86, 7606-7610. (Pubitemid 19254505)
158. Griffin, W. S. (2006). Inflammation and neurodegenerative diseases. American Journal of Clinical Nutrition, 83, 470S-474S. (Pubitemid 44713221)
159. Griffin, B., Selassie, M., & Gwebu, E. T. (2000). Aged garlic extract suppresses lipid peroxidation induced by beta-amyloid in PC12 cells. In Vitro Cellular & Developmental Biology. Animal, 36, 279-280. (Pubitemid 30619590)
160. Griffin, W. S., Sheng, J. G., Gentleman, S. M., Graham, D. I., Mrak, R. E., & Roberts, G. W. (1994). Microglial interleukin-1 alpha expression in human head injury: Correlations with neuronal and neuritic beta-amyloid precursor protein expression. Neuroscience Letters, 176, 133-136.
161. Griffin, W. S., Sheng, J. G., Roberts, G. W., & Mrak, R. E. (1995). Interleukin-1 expression in different plaque types in Alzheimer's disease: Significance in plaque evolution. Journal of Neuropathology and Experimental Neurology, 54, 276-281.
162. Grundman, M., & Delaney, P. (2002). Antioxidant strategies for Alzheimer's disease. Proceedings of the Nutrition Society, 61, 191-202. (Pubitemid 34665793)
163. Gu, Y., Dee, C. M., & Shen, J. (2011a). Interaction of free radicals, matrix metalloproteinases and caveolin-1 impacts blood-brain barrier permeability. Frontiers in Bioscience (Scholar Edition), 3, 1216-1231.
164. Gu, Y., Nieves, J. W., Luchsinger, J. A., & Scarmeas, N. (2011b). Dietary inflammation factor rating system and risk of Alzheimer disease in elders. Alzheimer Disease and Associated Disorders, 25, 149-154.
165. Guo, Q., Fu, W., Sopher, B. L., Miller, M. W., Ware, C. B., Martin, G. M., et al. (1999). Increased vulnerability of hippocampal neurons to excitotoxic necrosis in presenilin-1 mutant knock-in mice. Nature Medicine, 5, 101-106. (Pubitemid 29051006)
166. Gupta, M. K., Neelakantan, T. V., Sanghamitra, M., Tyagi, R. K., Dinda, A., Maulik, S., et al. (2006). An assessment of the role of reactive oxygen species and redox signaling in norepinephrineinduced apoptosis and hypertrophy of H9c2 cardiac myoblasts. Antioxidants & Redox Signaling, 8, 1081-1093.
167. Gutierrez, J., Ballinger, S. W., Darley-Usmar, V. M., & Landar, A. (2006). Free radicals, mitochondria, and oxidized lipids: The emerging role in signal transduction in vascular cells. Circulation Research, 99, 924-932. (Pubitemid 44657795)
168. Haddad, J. J. (2002). Antioxidant and prooxidant mechanisms in the regulation of redox(y)-sensitive transcription factors. Cellular Signalling, 14, 879-897. (Pubitemid 35247561)
169. Haddad, J. J. (2003). Science review: Redox and oxygen-sensitive transcription factors in the regulation of oxidant-mediated lung injury: Role for hypoxia-inducible factor-1alpha. Critical Care, 7, 47-54. (Pubitemid 36204269)
170. Haorah, J., Ramirez, S. H., Schall, K., Smith, D., Pandya, R., & Persidsky, Y. (2007). Oxidative stress activates protein tyrosine kinase and matrix metalloproteinases leading to blood-brain barrier dysfunction. Journal of Neurochemistry, 101, 566-576. (Pubitemid 46525283)
171. Hawkins, B. T., Lundeen, T. F., Norwood, K. M., Brooks, H. L., & Egleton, R. D. (2007). Increased blood-brain barrier permeability and altered tight junctions in experimental diabetes in the rat: Contribution of hyperglycaemia and matrix metalloproteinases. Diabetologia, 50, 202-211. (Pubitemid 46035869)
172. Heimlich, G., & Cidlowski, J. A. (2006). Selective role of intracellular chloride in the regulation of the intrinsic but not extrinsic pathway of apoptosis in Jurkat T-cells. The Journal of Biological Chemistry, 281, 2232-2241. (Pubitemid 43845814)
173. Helzner, E. P., Scarmeas, N., Cosentino, S., Tang, M. X., Schupf, N., & Stern, Y. (2008). Survival in Alzheimer disease: A multiethnic, population-based study of incident cases. Neurology, 71, 1489-1495.
174. Heneka, M. T., & O'Banion, M. K. (2007). Inflammatory processes in Alzheimer's disease. Journal of Neuroimmunology, 184, 69-91. (Pubitemid 46365992)
175. Heneka, M. T., O'Banion, M. K., Terwel, D., & Kummer, M. P. (2010). Neuroinflammatory processes in Alzheimer's disease. Journal of Neural Transmission, 117, 919-947.
176. Hensley, K., Mhatre, M., Mou, S., Pye, Q. N., Stewart, C., West, M., et al. (2006). On the relation of oxidative stress to neuroinflammation: Lessons learned from the G93A-SOD1 mouse model of amyotrophic lateral sclerosis. Antioxidants & Redox Signaling, 8, 2075-2087. (Pubitemid 46489632)
177. Heo, H. J., Cho, H. Y., Hong, B., Kim, H. K., Kim, E. K., Kim, B. G., et al. (2001). Protective effect of 4',5-dihydroxy-3',6,7-trimethoxyflavone from Artemisia asiatica against Abeta-induced oxidative stress in PC12 cells. Amyloid, 8, 194-201. (Pubitemid 32911605)
178. Hernanz, A., De la Fuente, M., Navarro, M., & Frank, A. (2007). Plasma aminothiol compounds, but not serum tumor necrosis factor receptor II and soluble receptor for advanced glycation end products, are related to the cognitive impairment in Alzheimer's disease and mild cognitive impairment patients. Neuroimmunomodulation, 14, 163-167. (Pubitemid 350249112)
179. Herring, A., Blome, M., Ambree, O., Sachser, N., Paulus, W., & Keyvani, K. (2010). Reduction of cerebral oxidative stress following environmental enrichment in mice with Alzheimerlike pathology. Brain Pathology, 20, 166-175.
180. Hirsch-Reinshagen, V., Burgess, B. L., & Wellington, C. L. (2009). Why lipids are important for Alzheimer disease? Molecular and Cellular Biochemistry, 326, 121-129.
181. Hong, H., Liu, L. P., Liao, J. M., Wang, T. S., Ye, F. Y., Wu, J., et al. (2009). Downregulation of LRP1 [correction of LPR1] at the blood-brain barrier in streptozotocin-induced diabetic mice. Neuropharmacology, 56, 1054-1059.
182. Horstmann, S., Budig, L., Gardner, H., Koziol, J., Deuschle, M., Schilling, C., et al. (2010). Matrix metalloproteinases in peripheral blood and cerebrospinal fluid in patients with Alzheimer's disease. International Psychogeriatrics, 22, 966-972.
183. Huang, X., Moir, R. D., Tanzi, R. E., Bush, A. I., & Rogers, J. T. (2004). Redox-active metals, oxidative stress, and Alzheimer's disease pathology. Annals of the New York Academy of Sciences, 1012, 153-163. (Pubitemid 38453522)
184. Hyodo, F., Chuang, K. H., Goloshevsky, A. G., Sulima, A., Griffiths, G. L., Mitchell, J. B., et al. (2008). Brain redox imaging using blood-brain barrier-permeable nitroxide MRI contrast agent. Journal of Cerebral Blood Flow and Metabolism, 28, 1165-1174. (Pubitemid 351733355)
185. Igarashi, Y., Utsumi, H., Chiba, H., Yamada-Sasamori, Y., Tobioka, H., Kamimura, Y., et al. (1999). Glial cell line-derived neurotrophic factor induces barrier function of endothelial cells forming the blood-brain barrier. Biochemical and Biophysical Research Communications, 261, 108-112. (Pubitemid 29371626)
186. Ill-Raga, G., Ramos-Fernandez, E., Guix, F. X., Tajes, M., Bosch-Morato, M., Palomer, E., et al. (2010). Amyloid-beta peptide fibrils induce nitro-oxidative stress in neuronal cells. Journal of Alzheimer's Disease, 22, 641-652.
187. Jaeger, L. B., Dohgu, S., Hwang, M. C., Farr, S. A., Murphy, M. P., Fleegal-DeMotta, M. A., et al. (2009a). Testing the neurovascular hypothesis of Alzheimer's disease: LRP-1 antisense reduces blood-brain barrier clearance, increases brain levels of amyloid-beta protein, and impairs cognition. Journal of Alzheimer's Disease, 17, 553-570.
188. Jaeger, L. B., Dohgu, S., Sultana, R., Lynch, J. L., Owen, J. B., Erickson, M. A., et al. (2009b). Lipopolysaccharide alters the blood-brain barrier transport of amyloid beta protein: A mechanism for inflammation in the progression of Alzheimer's disease. Brain, Behavior, and Immunity, 23, 507-517.
189. Jeynes, B., & Provias, J. (2008). Evidence for altered LRP/RAGE expression in Alzheimer lesion pathogenesis. Current Alzheimer Research, 5, 432-437.
190. Ji, Y., Permanne, B., Sigurdsson, E. M., Holtzman, D. M., & Wisniewski, T. (2001). Amyloid beta40/42 clearance across the blood-brain barrier following intra-ventricular injections in wild-type, apoE knock-out and human apoE3 or E4 expressing transgenic mice. Journal of Alzheimer's Disease, 3, 23-30. (Pubitemid 32238247)
191. Jian Liu, K., & Rosenberg, G. A. (2005). Matrix metalloproteinases and free radicals in cerebral ischemia. Free Radical Biology and Medicine, 39, 71-80. (Pubitemid 40733117)
192. John, G. R., Chen, L., Rivieccio, M. A., Melendez-Vasquez, C. V., Hartley, A., & Brosnan, C. F. (2004). Interleukin-1beta induces a reactive astroglial phenotype via deactivation of the Rho GTPase-Rock axis. Journal of Neuroscience, 24, 2837-2845. (Pubitemid 38380962)
193. Jomova, K., Vondrakova, D., Lawson, M., & Valko, M. (2010). Metals, oxidative stress and neurodegenerative disorders. Molecular and Cellular Biochemistry, 345, 91-104.
194. Joseph, J. A., Denisova, N., Villalobos-Molina, R., Erat, S., & Strain, J. (1996). Oxidative stress and age-related neuronal deficits. Molecular and Chemical Neuropathology, 28, 35-40. (Pubitemid 26275048)
195. 2 or 2,2-azobis-(2-amidinopropane) dihydrochloride by the glutathione mimetic tricyclodecan-9-ylxanthogenate. Free Radical Biology and Medicine, 38, 1023-1031. (Pubitemid 40386548)
196. Kalaria, R. N. (1997). Cerebrovascular degeneration is related to amyloid-beta protein deposition in Alzheimer's disease. Annals of the New York Academy of Sciences, 826, 263-271. (Pubitemid 27478048)
197. Kalaria, R. N. (2002). Small vessel disease and Alzheimer's dementia: Pathological considerations. Cerebrovascular Diseases, 13(Suppl 2), 48-52. (Pubitemid 34233909)
198. Kalaria, R. N., & Harik, S. I. (1989). Reduced glucose transporter at the blood-brain barrier and in cerebral cortex in Alzheimer disease. Journal of Neurochemistry, 53, 1083-1088. (Pubitemid 19238473)
199. Kang, R., Tang, D., Loze, M. T., & Zeh, H. J. (2011). Apoptosis to autophagy switch triggered by the MHC class III-encoded receptor for advanced glycation endproducts (RAGE). Autophagy, 7, 91-93.
200. Kanski, J., Aksenova, M., Schoneich, C., & Butterfield, D. A. (2002). Substitution of isoleucine-31 by helical-breaking proline abolishes oxidative stress and neurotoxic properties of Alzheimer's amyloid beta-peptide. Free Radical Biology and Medicine, 32, 1205-1211. (Pubitemid 34603357)
201. Kawai, M., Kalaria, R. N., Harik, S. I., & Perry, G. (1990). The relationship of amyloid plaques to cerebral capillaries in Alzheimer's disease. American Journal of Pathology, 137, 1435-1446.
202. Kawas, C. H., & Corrada, M. M. (2006). Alzheimer's and dementia in the oldest-old: A century of challenges. Current Alzheimer Research, 3, 411-419. (Pubitemid 46066420)
203. Kingsley, M. (2006). Effects of phosphatidylserine supplementation on exercising humans. Sports Medicine, 36, 657-669. (Pubitemid 44161955)
204. Kitamura, Y. (1998). Functional activation of glial cells in early and delayed episodes of the brain damage. Nippon Yakurigaku Zasshi, 111, 147-156. (Pubitemid 28143992)
205. Klegeris, A., Walker, D. G., & McGeer, P. L. (1997). Interaction of Alzheimer beta-amyloid peptide with the human monocytic cell line THP-1 results in a protein kinase C-dependent secretion of tumor necrosis factor-alpha. Brain Research, 747, 114-121. (Pubitemid 27063805)
206. Kobayashi, K., Hayashi, M., Nakano, H., Shimazaki, M., Sugimori, K., & Koshino, Y. (2004). Correlation between astrocyte apoptosis and Alzheimer changes in gray matter lesions in Alzheimer's disease. Journal of Alzheimer's Disease, 6, 623-632 (discussion 673-681). (Pubitemid 40164168)
207. Koczyk, D., & Oderfeld-Nowak, B. (2000). Long-term microglial and astroglial activation in the hippocampus of trimethyltin-intoxicated rat: Stimulation of NGF and TrkA immunoreactivities in astroglia but not in microglia. International Journal of Developmental Neuroscience, 18, 591-606. (Pubitemid 30407000)
208. Koistinaho, M., Lin, S., Wu, X., Esterman, M., Koger, D., Hanson, J., et al. (2004). Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-beta peptides. Nature Medicine, 10, 719-726. (Pubitemid 38937637)
209. Kovacic, P., & Somanathan, R. (2011). Cell signaling and receptors with resorcinols and flavonoids: Redox, reactive oxygen species, and physiological effects. Journal of Receptor and Signal Transduction Research, 31, 265-270.
210. Kurt, M. A., Davies, D. C., & Kidd, M. (1997). Paired helical filament morphology varies with intracellular location in Alzheimer's disease brain. Neuroscience Letters, 239, 41-44. (Pubitemid 28055845)
211. Laws, S. M., Perneczky, R., Wagenpfeil, S., Muller, U., Forstl, H., Martins, R. N., et al. (2005). TNF polymorphisms in Alzheimer disease and functional implications on CSF beta-amyloid levels. Human Mutation, 26, 29-35. (Pubitemid 40980700)
212. Le Sueur, L. P., Collares-Buzato, C. B., & da Cruz-Hofling, M. A. (2004). Mechanisms involved in the blood-brain barrier increased permeability induced by Phoneutria nigriventer spider venom in rats. Brain Research, 1027, 38-47. (Pubitemid 39370993)
213. Leake, A., Morris, C. M., & Whateley, J. (2000). Brain matrix metalloproteinase 1 levels are elevated in Alzheimer's disease. Neuroscience Letters, 291, 201-203. (Pubitemid 30657926)
214. Lecanu, L., Greeson, J., & Papadopoulos, V. (2006). Beta-amyloid and oxidative stress jointly induce neuronal death, amyloid deposits, gliosis, and memory impairment in the rat brain. Pharmacology, 76, 19-33. (Pubitemid 41759058)
215. Lee, R. K., Araki, W., & Wurtman, R. J. (1997). Stimulation of amyloid precursor protein synthesis by adrenergic receptors coupled to cAMP formation. Proceedings of the National Academy of Sciences of the United States of America, 94, 5422-5426. (Pubitemid 27214799)
216. Lee, Y. J., Han, S. B., Nam, S. Y., Oh, K. W., & Hong, J. T. (2010a). Inflammation and Alzheimer's disease. Archives of Pharmacal Research, 33, 1539-1556.
217. Lee, E. O., Kang, J. L., & Chong, Y. H. (2005). The amyloid-beta peptide suppresses transforming growth factor-beta1-induced matrix metalloproteinase-2 production via Smad7 expression in human monocytic THP-1 cells. The Journal of Biological Chemistry, 280, 7845-7853.
218. Lee, K. W., Kim, J. B., Seo, J. S., Kim, T. K., Im, J. Y., Baek, I. S., et al. (2009). Behavioral stress accelerates plaque pathogenesis in the brain of Tg2576 mice via generation of metabolic oxidative stress. Journal of Neurochemistry, 108, 165-175.
219. Lee, Y. H., Lee, N. H., Bhattarai, G., Yun, J. S., Kim, T. I., Jhee, E. C., et al. (2010b). PPARgamma inhibits inflammatory reaction in oxidative stress induced human diploid fibloblast. Cell Biochemistry and Function, 28, 490-496.
220. Lehner, C., Gehwolf, R., Tempfer, H., Krizbai, I., Hennig, B., Bauer, H. C., et al. (2011). Oxidative stress and blood-brain barrier dysfunction under particular consideration of matrix metalloproteinases. Antioxidants & Redox Signaling.
221. Levy, E., Prelli, F., & Frangione, B. (2006). Studies on the first described Alzheimer's disease amyloid beta mutant, the Dutch variant. Journal of Alzheimer's Disease, 9, 329-339. (Pubitemid 44253327)
222. Li, X., Alafuzoff, I., Soininen, H., Winblad, B., & Pei, J. J. (2005). Levels of mTOR and its downstream targets 4E-BP1, eEF2, and eEF2 kinase in relationships with tau in Alzheimer's disease brain. FEBS J, 272, 4211-4220. (Pubitemid 41160927)
223. Li, Y. J., Scott, W. K., Zhang, L., Lin, P. I., Oliveira, S. A., Skelly, T., et al. (2006). Revealing the role of glutathione S-transferase omega in age-at-onset of Alzheimer and Parkinson diseases. Neurobiology of Aging, 27, 1087-1093. (Pubitemid 43850638)
224. Liao, M. C., & Van Nostrand, W. E. (2010). Degradation of soluble and fibrillar amyloid beta-protein by matrix metalloproteinase (MT1-MMP) in vitro. Biochemistry, 49, 1127-1136.
225. Lim, G. P., Chu, T., Yang, F., Beech, W., Frautschy, S. A., & Cole, G. M. (2001a). The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. Journal of Neuroscience, 21, 8370-8377. (Pubitemid 33051435)
226. Lim, G. P., Yang, F., Chu, T., Gahtan, E., Ubeda, O., Beech, W., et al. (2001b). Ibuprofen effects on Alzheimer pathology and open field activity in APPsw transgenic mice. Neurobiology of Aging, 22, 983-991. (Pubitemid 34066567)
227. Lin, Y. L., Liu, C. C., Chuang, J. I., Lei, H. Y., Yeh, T. M., Lin, Y. S., et al. (2000). Involvement of oxidative stress, NF-IL-6, and RANTES expression in dengue-2-virus-infected human liver cells. Virology, 276, 114-126.
228. Liu, H., Funke, S. A., & Willbold, D. (2010). Transport of Alzheimer disease amyloid-beta-binding D-amino acid peptides across an in vitro blood-brain barrier model. Rejuvenation Research, 13, 210-213.
229. Liu, L. P., Hong, H., Liao, J. M., Wang, T. S., Wu, J., Chen, S. S., et al. (2009a). Upregulation of RAGE at the blood-brain barrier in streptozotocin-induced diabetic mice. Synapse, 63, 636-642.
230. Liu, Q., Zhang, J., Tran, H., Verbeek, M. M., Reiss, K., Estus, S., et al. (2009b). LRP1 shedding in human brain: roles of ADAM10 and ADAM17. Molecular Neurodegeneration, 4, 17.
231. Lochhead, J. J., McCaffrey, G., Quigley, C. E., Finch, J., DeMarco, K. M., Nametz, N., et al. (2010). Oxidative stress increases bloodbrain barrier permeability and induces alterations in occludin during hypoxia-reoxygenation. Journal of Cerebral Blood Flow and Metabolism, 30, 1625-1636.
232. Loh, K. P., Huang, S. H., De Silva, R., Tan, B. K., & Zhu, Y. Z. (2006). Oxidative stress: Apoptosis in neuronal injury. Current Alzheimer Research, 3, 327-337. (Pubitemid 44351476)
233. Lorenzl, S., Albers, D. S., Relkin, N., Ngyuen, T., Hilgenberg, S. L., Chirichigno, J., et al. (2003). Increased plasma levels of matrix metalloproteinase-9 in patients with Alzheimer's disease. Neurochemistry International, 43, 191-196. (Pubitemid 36422625)
234. Love, S. (1999). Oxidative stress in brain ischemia. Brain Pathology, 9, 119-131. (Pubitemid 29056523)
235. Lue, L. F., Yan, S. D., Stern, D. M., & Walker, D. G. (2005). Preventing activation of receptor for advanced glycation endproducts in Alzheimer's disease. Current Drug Targets. CNS and Neurological Disorders, 4, 249-266. (Pubitemid 40754161)
236. Lynch, T., Cherny, R. A., & Bush, A. I. (2000). Oxidative processes in Alzheimer's disease: The role of abeta-metal interactions. Experimental Gerontology, 35, 445-451. (Pubitemid 30665820)
237. Ma, G. J. (1987). The relationship of astrocyte activation and fibrous gliosis to the development of Alzheimer type I cells in Wilson disease. Zhonghua Bing Li Xue Za Zhi, 16, 7-10.
238. Maccioni, R. B., Rojo, L. E., Fernandez, J. A., & Kuljis, R. O. (2009). The role of neuroimmunomodulation in Alzheimer's disease. Annals of the New York Academy of Sciences, 1153, 240-246.
239. Mancuso, M., Orsucci, D., LoGerfo, A., Calsolaro, V., & Siciliano, G. (2010). Clinical features and pathogenesis of Alzheimer's disease: Involvement of mitochondria and mitochondrial DNA. Advances in Experimental Medicine and Biology, 685, 34-44.
240. Mancuso, C., Scapagini, G., Curro, D., Giuffrida Stella, A. M., De Marco, C., Butterfield, D. A., et al. (2007). Mitochondrial dysfunction, free radical generation and cellular stress response in neurodegenerative disorders. Frontiers in Bioscience, 12, 1107-1123. (Pubitemid 46846882)
241. Marchesi, V. T. (2011). Alzheimer's dementia begins as a disease of small blood vessels, damaged by oxidative-induced inflammation and dysregulated amyloid metabolism: Implications for early detection and therapy. FASEB J, 25, 5-13.
242. Markesbery, W. R., & Carney, J. M. (1999). Oxidative alterations in Alzheimer's disease. Brain Pathology, 9, 133-146. (Pubitemid 29056524)
243. Martin-Aragon, S., Bermejo-Bescos, P., Benedi, J., Felici, E., Gil, P., Ribera, J. M., et al. (2009). Metalloproteinase's activity and oxidative stress in mild cognitive impairment and Alzheimer's disease. Neurochemical Research, 34, 373-378.
244. Masliah, E., Raber, J., Alford, M., Mallory, M., Mattson, M. P., Yang, D., et al. (1998). Amyloid protein precursor stimulates excitatory amino acid transport. Implications for roles in neuroprotection and pathogenesis. The Journal of Biological Chemistry, 273, 12548-12554. (Pubitemid 28240630)
245. Matos, M., Augusto, E., Oliveira, C. R., & Agostinho, P. (2008). Amyloid-beta peptide decreases glutamate uptake in cultured astrocytes: involvement of oxidative stress and mitogen-activated protein kinase cascades. Neuroscience, 156, 898-910.
246. Mattson, M. P. (1994). Calcium and neuronal injury in Alzheimer's disease. Contributions of beta-amyloid precursor protein mismetabolism, free radicals, and metabolic compromise. Annals of the New York Academy of Sciences, 747, 50-76.
247. Mattson, M. P., & Chan, S. L. (2003). Neuronal and glial calcium signaling in Alzheimer's disease. Cell Calcium, 34, 385-397. (Pubitemid 37021231)
248. Mattson, M. P., Cheng, B., Davis, D., Bryant, K., Lieberburg, I., & Rydel, R. E. (1992). Beta-amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. Journal of Neuroscience, 12, 376-389.
249. Mattson, M. P., Pedersen, W. A., Duan, W., Culmsee, C., & Camandola, S. (1999). Cellular and molecular mechanisms underlying perturbed energy metabolism and neuronal degeneration in Alzheimer's and Parkinson's diseases. Annals of the New York Academy of Sciences, 893, 154-175. (Pubitemid 30038074)
250. McAlpine, F. E., Lee, J. K., Harms, A. S., Ruhn, K. A., Blurton-Jones, M., Hong, J., et al. (2009). Inhibition of soluble TNF signaling in a mouse model of Alzheimer's disease prevents pre-plaque amyloid-associated neuropathology. Neurobiology of Diseases, 34, 163-177.
251. McConlogue, L., Buttini, M., Anderson, J. P., Brigham, E. F., Chen, K. S., Freedman, S. B., et al. (2007). Partial reduction of BACE1 has dramatic effects on Alzheimer plaque and synaptic pathology in APP Transgenic Mice. The Journal of Biological Chemistry, 282, 26326-26334. (Pubitemid 47443774)
252. McNiff, P. A., Laliberte, R. E., Svensson, L., Pazoles, C. J., & Gabel, C. A. (1995). Inhibition of cytokine activation processes in vitro by tenidap, a novel anti-inflammatory agent. Cytokine, 7, 196-208.
253. Medeiros, R., Prediger, R. D., Passos, G. F., Pandolfo, P., Duarte, F. S., Franco, J. L., et al. (2007). Connecting TNF-alpha signaling pathways to iNOS expression in a mouse model of Alzheimer's disease: Relevance for the behavioral and synaptic deficits induced by amyloid beta protein. Journal of Neuroscience, 27, 5394-5404. (Pubitemid 46790177)
254. Mehlhorn, G., Hollborn, M., & Schliebs, R. (2000). Induction of cytokines in glial cells surrounding cortical beta-amyloid plaques in transgenic Tg2576 mice with Alzheimer pathology. International Journal of Developmental Neuroscience, 18, 423-431. (Pubitemid 30243072)
255. Mhatre, M., Floyd, R. A., & Hensley, K. (2004). Oxidative stress and neuroinflammation in Alzheimer's disease and amyotrophic lateral sclerosis: Common links and potential therapeutic targets. Journal of Alzheimer's Disease, 6, 147-157. (Pubitemid 38560250)
256. Middeldorp, J., van den Berge, S. A., Aronica, E., Speijer, D., & Hol, E. M. (2009). Specific human astrocyte subtype revealed by affinity purified GFAP antibody; unpurified serum cross-reacts with neurofilament-L in Alzheimer. PLoS One, 4, e7663.
257. Minter, R. M., Rectenwald, J. E., Fukuzuka, K., Tannahill, C. L., La Face, D., Tsai, V., et al. (2000). TNF-alpha receptor signaling and IL-10 gene therapy regulate the innate and humoral immune responses to recombinant adenovirus in the lung. Journal of Immunology, 164, 443-451. (Pubitemid 30013020)
258. Misonou, H., Morishima-Kawashima, M., & Ihara, Y. (2000). Oxidative stress induces intracellular accumulation of amyloid beta-protein (Abeta) in human neuroblastoma cells. Biochemistry, 39, 6951-6959. (Pubitemid 30390389)
259. Miyakawa, T. (2010). Vascular pathology in Alzheimer's disease. Psychogeriatrics, 10, 39-44.
260. Mlekusch, R., & Humpel, C. (2009). Matrix metalloproteinases-2 and -3 are reduced in cerebrospinal fluid with low beta-amyloid1-42 levels. Neuroscience Letters, 466, 135-138.
261. Moreira, P. I., Santos, M. S., Oliveira, C. R., Shenk, J. C., Nunomura, A., Smith, M. A., et al. (2008). Alzheimer disease and the role of free radicals in the pathogenesis of the disease. CNS & Neurological Disorders Drug Targets, 7, 3-10. (Pubitemid 351516211)
262. Mosley, R. L., Benner, E. J., Kadiu, I., Thomas, M., Boska, M. D., Hasan, K., et al. (2006). Neuroinflammation, oxidative stress and the pathogenesis of Parkinson's disease. Clinical Neuroscience Research, 6, 261-281. (Pubitemid 44849177)
263. Mrak, R. E., & Griffinbc, W. S. (2001). The role of activated astrocytes and of the neurotrophic cytokine S100B in the pathogenesis of Alzheimer's disease. Neurobiology of Aging, 22, 915-922. (Pubitemid 34066559)
264. Multhaup, G. (2006). Amyloid precursor protein and BACE function as oligomers. Neurodegenerative Diseases, 3, 270-274. (Pubitemid 44600314)
265. Nadler, Y., Alexandrovich, A., Grigoriadis, N., Hartmann, T., Rao, K. S., Shohami, E., et al. (2008). Increased expression of the gamma-secretase components presenilin-1 and nicastrin in activated astrocytes and microglia following traumatic brain injury. Glia, 56, 552-567.
266. Nalivaeva, N. N., Fisk, L. R., Belyaev, N. D., & Turner, A. J. (2008). Amyloid-degrading enzymes as therapeutic targets in Alzheimer's disease. Current Alzheimer Research, 5, 212-224. (Pubitemid 351536346)
267. Nanetti, L., Vignini, A., Moroni, C., Bartolini, M., Luzzi, S., Provinciali, L., et al. (2005). Peroxynitrite production and NOS expression in astrocytes U373MG incubated with lipoproteins from Alzheimer patients. Brain Research, 1054, 38-44. (Pubitemid 41188127)
268. Newby, A. C., Southgate, K. M., & Davies, M. (1994). Extracellular matrix degrading metalloproteinases in the pathogenesis of arteriosclerosis. Basic Research in Cardiology, 89(Suppl 1), 59-70. (Pubitemid 24314598)
269. Newman, M., Musgrave, I. F., & Lardelli, M. (2007). Alzheimer disease: Amyloidogenesis, the presenilins and animal models. Biochimica et Biophysica Acta, 1772, 285-297. (Pubitemid 46275437)
270. Niki, E. (2009). Lipid peroxidation: physiological levels and dual biological effects. Free Radical Biology and Medicine, 47, 469-484.
271. Onyango, I. G., & Khan, S. M. (2006). Oxidative stress, mitochondrial dysfunction, and stress signaling in Alzheimer's disease. Current Alzheimer Research, 3, 339-349. (Pubitemid 44351477)
272. Op den Velde, W., & Stam, F. C. (1976). Some cerebral proteins and enzyme systems in Alzheimer's presenile and senile dementia. Journal of the American Geriatrics Society, 24, 12-16.
273. Opii, W. O., Sultana, R., Abdul, H. M., Ansari, M. A., Nath, A., & Butterfield, D. A. (2007). Oxidative stress and toxicity induced by the nucleoside reverse transcriptase inhibitor (NRTI)-2',3'-dideoxycytidine (ddC): Relevance to HIV-dementia. Experimental Neurology, 204, 29-38. (Pubitemid 46330254)
274. Orrenius, S. (2004). Mitochondrial regulation of apoptotic cell death. Toxicology Letters, 149, 19-23. (Pubitemid 38469816)
275. Owen, J. B., Sultana, R., Aluise, C. D., Erickson, M. A., Price, T. O., Bu, G., et al. (2010). Oxidative modification to LDL receptor-related protein 1 in hippocampus from subjects with Alzheimer disease: Implications for Abeta accumulation in AD brain. Free Radical Biology and Medicine, 49, 1798-1803.
276. Palade, F., Alexa, I. D., Azoicai, D., Panaghiu, L., & Ungureanu, G. (2003). Oxidative stress in atherosclerosis. Revista Medico-Chirurgicala A Societatii de Medici si Naturalisti din Iasi, 107, 502-511.
277. Pallas, M., Camins, A., Smith, M. A., Perry, G., Lee, H. G., & Casadesus, G. (2008). From aging to Alzheimer's disease: unveiling "the switch" with the senescence-accelerated mouse model (SAMP8). Journal of Alzheimer's Disease, 15, 615-624.
278. Pan, W., Solomon, B., Maness, L. M., & Kastin, A. J. (2002). Antibodies to beta-amyloid decrease the blood-to-brain transfer of beta-amyloid peptide. Experimental Biology and Medicine (Maywood), 227, 609-615.
279. Paoletti, F., Mocali, A., & Tombaccini, D. (1997). Cysteine proteinases are responsible for characteristic transketolase alterations in Alzheimer fibroblasts. Journal of Cellular Physiology, 172, 63-68. (Pubitemid 27283348)
280. Papassotiropoulos, A., Hock, C., & Nitsch, R. M. (2001). Genetics of interleukin 6: Implications for Alzheimer's disease. Neurobiology of Aging, 22, 863-871. (Pubitemid 34066553)
281. Pardridge, W. M. (1988). Does the brain's gatekeeper falter in aging? Neurobiology of Aging, 9, 44-46.
282. Parks, J. K., Smith, T. S., Trimmer, P. A., Bennett, J. P., Jr., & Parker, W. D., Jr. (2001). Neurotoxic Abeta peptides increase oxidative stress in vivo through NMDA-receptor and nitric-oxide-synthase mechanisms, and inhibit complex IV activity and induce a mitochondrial permeability transition in vitro. Journal of Neurochemistry, 76, 1050-1056. (Pubitemid 32167378)
283. Pasparakis, M., Alexopoulou, L., Episkopou, V., & Kollias, G. (1996). Immune and inflammatory responses in TNF alpha-deficient mice: A critical requirement for TNF alpha in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune response. Journal of Experimental Medicine, 184, 1397-1411. (Pubitemid 26354696)
284. Pattison, D. I., Dean, R. T., & Davies, M. J. (2002). Oxidation of DNA, proteins and lipids by DOPA, protein-bound DOPA, and related catechol(amine)s. Toxicology, 177, 23-37. (Pubitemid 34786242)
285. Paul, R., Lorenzl, S., Koedel, U., Sporer, B., Vogel, U., Frosch, M., et al. (1998). Matrix metalloproteinases contribute to the bloodbrain barrier disruption during bacterial meningitis. Annals of Neurology, 44, 592-600. (Pubitemid 28477846)
286. Pedersen, N. L., Berg, S., Johansson, B., Johansson, K., Viitanen, M., Winblad, B., et al. (1998). Genetic factors are often found in Alzheimer disease. An extensive twin study to clarify the heredity-environment relationship. Lakartidningen, 95, 2585-2588. (Pubitemid 128641139)
287. Pereira, C., Santos, M. S., & Oliveira, C. (1999). Involvement of oxidative stress on the impairment of energy metabolism induced by A beta peptides on PC12 cells: Protection by antioxidants. Neurobiology of Diseases, 6, 209-219. (Pubitemid 29297822)
288. Pflanzner, T., Janko, M. C., Andre-Dohmen, B., Reuss, S., Weggen, S., Roebroek, A. J., et al. (2010). LRP1 mediates bidirectional transcytosis of amyloid-beta across the blood-brain barrier. Neurobiology of Aging. doi:10.1016/j.neurobiolaging.2010. 05.025.
289. Pike, C. J., Walencewicz, A. J., Glabe, C. G., & Cotman, C. W. (1991). In vitro aging of beta-amyloid protein causes peptide aggregation and neurotoxicity. Brain Research, 563, 311-314.
290. Pillai, S., Oresajo, C., & Hayward, J. (2005). Ultraviolet radiation and skin aging: Roles of reactive oxygen species, inflammation and protease activation, and strategies for prevention of inflammation-induced matrix degradation - A review. International Journal of Cosmetic Science, 27, 17-34. (Pubitemid 40313411)
291. Pimplikar, S. W. (2009). Reassessing the amyloid cascade hypothesis of Alzheimer's disease. International Journal of Biochemistry and Cell Biology, 41, 1261-1268.
292. Poleshchuk, N. N., Votyakov, V. I., Ilkevich Yu, G., Duboiskaya, G. P., Grigoriev, D. G., & Kolomiets, N. D. (1992). Structural and functional changes of blood-brain barrier and indication of prion amyloid filaments in experimental amyotrophic leucospongiosis. Acta Virologica, 36, 293-303.
293. Popescu, B. O., Toescu, E. C., Popescu, L. M., Bajenaru, O., Muresanu, D. F., Schultzberg, M., et al. (2009). Blood-brain barrier alterations in ageing and dementia. Journal of the Neurological Sciences, 283, 99-106.
294. Pratico, D., Uryu, K., Leight, S., Trojanoswki, J. Q., & Lee, V. M. (2001). Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. Journal of Neuroscience, 21, 4183-4187. (Pubitemid 32538543)
295. Price, D. L., Sisodia, S. S., & Gandy, S. E. (1995). Amyloid beta amyloidosis in Alzheimer's disease. Current Opinion in Neurology, 8, 268-274.
296. Pun, P. B., Lu, J., & Moochhala, S. (2009). Involvement of ROS in BBB dysfunction. Free Radical Research, 43, 348-364.
297. Putcha, G. V., Harris, C. A., Moulder, K. L., Easton, R. M., Thompson, C. B., & Johnson, E. M., Jr. (2002). Intrinsic and extrinsic pathway signaling during neuronal apoptosis: Lessons from the analysis of mutant mice. Journal of Cell Biology, 157, 441-453. (Pubitemid 34839808)
298. Ramirez, S. H., Potula, R., Fan, S., Eidem, T., Papugani, A., Reichenbach, N., et al. (2009). Methamphetamine disrupts blood-brain barrier function by induction of oxidative stress in brain endothelial cells. Journal of Cerebral Blood Flow and Metabolism, 29, 1933-1945.
299. Rathke-Hartlieb, S., Schmidt, V. C., Jockusch, H., Schmitt-John, T., & Bartsch, J. W. (1999). Spatiotemporal progression of neuro-degeneration and glia activation in the wobbler neuropathy of the mouse. Neuroreport, 10, 3411-3416.
300. Readnower, R. D., Chavko, M., Adeeb, S., Conroy, M. D., Pauly, J. R., McCarron, R. M., et al. (2010). Increase in blood-brain barrier permeability, oxidative stress, and activated microglia in a rat model of blast-induced traumatic brain injury. Journal of Neuroscience Research, 88, 3530-3539.
301. Reale, M., Iarlori, C., Gambi, F., Feliciani, C., Salone, A., Toma, L., et al. (2004). Treatment with an acetylcholinesterase inhibitor in Alzheimer patients modulates the expression and production of the pro-inflammatory and anti-inflammatory cytokines. Journal of Neuroimmunology, 148, 162-171. (Pubitemid 38229569)
302. Reed, T., Perluigi, M., Sultana, R., Pierce, W. M., Klein, J. B., Turner, D. M., et al. (2008). Redox proteomic identification of 4-hydroxy-2-nonenal- modified brain proteins in amnestic mild cognitive impairment: Insight into the role of lipid peroxidation in the progression and pathogenesis of Alzheimer's disease. Neurobiology of Diseases, 30, 107-120.
303. Reiter, R. J. (1993). Interactions of the pineal hormone melatonin with oxygen-centered free radicals: A brief review. Brazilian Journal of Medical and Biological Research, 26, 1141-1155.
304. Rogers, J. T., Bush, A. I., Cho, H. H., Smith, D. H., Thomson, A. M., Friedlich, A. L., et al. (2008). Iron and the translation of the amyloid precursor protein (APP) and ferritin mRNAs: Riboregulation against neural oxidative damage in Alzheimer's disease. Biochemical Society Transactions, 36, 1282-1287.
305. Rogers, J. T., & Lahiri, D. K. (2004). Metal and inflammatory targets for Alzheimer's disease. Current Drug Targets, 5, 535-551. (Pubitemid 39004428)
306. Roggo, S. (2002). Inhibition of BACE, a promising approach to Alzheimer's disease therapy. Current Topics in Medicinal Chemistry, 2, 359-370.
307. Rohl, C., Armbrust, E., Herbst, E., Jess, A., Gulden, M., Maser, E., et al. (2010). Mechanisms involved in the modulation of astroglial resistance to oxidative stress induced by activated microglia: Antioxidative systems, peroxide elimination, radical generation, lipid peroxidation. Neurotoxicity Research, 17, 317-331.
308. Rong, L. L., Gooch, C., Szabolcs, M., Herold, K. C., Lalla, E., Hays, A. P., et al. (2005). RAGE: a journey from the complications of diabetes to disorders of the nervous system - Striking a fine balance between injury and repair. Restorative Neurology and Neuroscience, 23, 355-365. (Pubitemid 41746169)
309. Rosenberg, G. A., Estrada, E. Y., & Dencoff, J. E. (1998). Matrix metalloproteinases and TIMPs are associated with blood-brain barrier opening after reperfusion in rat brain. Stroke, 29, 2189-2195. (Pubitemid 28443538)
310. Rosenberg, R. N., Richter, R. W., Risser, R. C., Taubman, K., Prado-Farmer, I., Ebalo, E., et al. (1996). Genetic factors for the development of Alzheimer disease in the Cherokee Indian. Archives of Neurology, 53, 997-1000. (Pubitemid 26340035)
311. Rosi, S., Ramirez-Amaya, V., Hauss-Wegrzyniak, B., & Wenk, G. L. (2004). Chronic brain inflammation leads to a decline in hippocampal NMDA-R1 receptors. Journal of Neuroinflammation, 1, 12.
312. Rossner, S., Lange-Dohna, C., Zeitschel, U., & Perez-Polo, J. R. (2005). Alzheimer's disease beta-secretase BACE1 is not a neuronspecific enzyme. Journal of Neurochemistry, 92, 226-234. (Pubitemid 40194014)
313. Roth, K. A. (2001). Caspases, apoptosis, and Alzheimer disease: causation, correlation, and confusion. Journal of Neuropathology and Experimental Neurology, 60, 829-838.
314. Roth, A. D., Ramirez, G., Alarcon, R., & Von Bernhardi, R. (2005). Oligodendrocytes damage in Alzheimer's disease: Beta amyloid toxicity and inflammation. Biological Research, 38, 381-387.
315. Rowlands, D. J., Chapple, S., Siow, R. C., & Mann, G. E. (2011). Equol-stimulated mitochondrial reactive oxygen species activate endothelial nitric oxide synthase and redox signaling in endothelial cells: Roles for F-actin and GPR30. Hypertension, 57, 833-840.
316. Saarela, M. S., Lehtimaki, T., Rinne, J. O., Hervonen, A., Jylha, M., Roytta, M., et al. (2004). Interaction between matrix metalloproteinase 3 and the epsilon4 allele of apolipoprotein E increases the risk of Alzheimer's disease in Finns. Neuroscience Letters, 367, 336-339. (Pubitemid 39178608)
317. Saiz, P. A., Garcia-Portilla, M. P., Florez, G., Corcoran, P., Arango, C., Morales, B., et al. (2009). Polymorphisms of the IL-1 gene complex are associated with alcohol dependence in Spanish Caucasians: Data from an association study. Alcoholism, Clinical and Experimental Research, 33, 2147-2153.
318. Sazontova, T. G., Anchishkina, N. A., Zhukova, A. G., Bedareva, I. V., Pylaeva, E. A., Kriventsova, N. A., et al. (2008). Reactive oxygen species and redox-signaling during adaptation to changes of oxygen level. Fiziolohichnyǐ Zhurnal, 54, 18-32.
319. Schmidt, J., Barthel, K., Wrede, A., Salajegheh, M., Bahr, M., & Dalakas, M. C. (2008). Interrelation of inflammation and APP in sIBM: IL-1 beta induces accumulation of beta-amyloid in skeletal muscle. Brain, 131, 1228-1240.
320. Schmidt, A. M., Hori, O., Cao, R., Yan, S. D., Brett, J., Wautier, J. L., et al. (1996). RAGE: A novel cellular receptor for advanced glycation end products. Diabetes, 45(Suppl 3), S77-S80.
321. Schroder, R., & Linke, R. P. (1999). Cerebrovascular involvement in systemic AA and AL amyloidosis: A clear haematogenic pattern. Virchows Archiv, 434, 551-560. (Pubitemid 29281315)
322. Schubert, P., Ogata, T., Marchini, C., & Ferroni, S. (2001). Gliarelated pathomechanisms in Alzheimer's disease: A therapeutic target? Mechanisms of Ageing and Development, 123, 47-57. (Pubitemid 32972258)
323. Schubert, P., & Rudolphi, K. (1998). Interfering with the pathologic activation of microglial cells and astrocytes in dementia. Alzheimer Disease and Associated Disorders, 12(Suppl 2), S21-S28. (Pubitemid 29108223)
324. Schulz, T. J., Westermann, D., Isken, F., Voigt, A., Laube, B., Thierbach, R., et al. (2010). Activation of mitochondrial energy metabolism protects against cardiac failure. Aging (Albany NY), 2, 843-853.
325. Sekut, L., & Connolly, K. (1998). AntiTNF-alpha agents in the treatment of inflammation. Expert Opinion on Investigational Drugs, 7, 1825-1839.
326. Senthilkumar, K., Elumalai, P., Arunkumar, R., Banudevi, S., Gunadharini, N. D., Sharmila, G., et al. (2010). Quercetin regulates insulin like growth factor signaling and induces intrinsic and extrinsic pathway mediated apoptosis in androgen independent prostate cancer cells (PC-3). Molecular and Cellular Biochemistry, 344, 173-184.
327. Sergeant, N., Wattez, A., Galvan-valencia, M., Ghestem, A., David, J. P., Lemoine, J., et al. (2003). Association of ATP synthase alpha-chain with neurofibrillary degeneration in Alzheimer's disease. Neuroscience, 117, 293-303. (Pubitemid 36259745)
328. Serretti, A., Olgiati, P., & De Ronchi, D. (2007). Genetics of Alzheimer's disease. A rapidly evolving field. Journal of Alzheimer's Disease, 12, 73-92. (Pubitemid 47396303)
329. Shaftel, S. S., Griffin, W. S., & O'Banion, M. K. (2008). The role of interleukin-1 in neuroinflammation and Alzheimer disease: An evolving perspective. Journal of Neuroinflammation, 5, 7.
330. Shalit, F., Sredni, B., Stern, L., Kott, E., & Huberman, M. (1994). Elevated interleukin-6 secretion levels by mononuclear cells of Alzheimer's patients. Neuroscience Letters, 174, 130-132. (Pubitemid 24199480)
331. Shao, Y., Gearing, M., & Mirra, S. S. (1997). Astrocyte- apolipoprotein E associations in senile plaques in Alzheimer disease and vascular lesions: A regional immunohistochemical study. Journal of Neuropathology and Experimental Neurology, 56, 376-381. (Pubitemid 27465020)
332. Shelat, P. B., Chalimoniuk, M., Wang, J. H., Strosznajder, J. B., Lee, J. C., Sun, A. Y., et al. (2008). Amyloid beta peptide and NMDA induce ROS from NADPH oxidase and AA release from cytosolic phospholipase A2 in cortical neurons. Journal of Neurochemistry, 106, 45-55. (Pubitemid 351840199)
333. Sheng, B., Gong, K., Niu, Y., Liu, L., Yan, Y., Lu, G., et al. (2009). Inhibition of gamma-secretase activity reduces Abeta production, reduces oxidative stress, increases mitochondrial activity and leads to reduced vulnerability to apoptosis: Implications for the treatment of Alzheimer's disease. Free Radical Biology and Medicine, 46, 1362-1375.
334. Sheng, J. G., Mrak, R. E., & Griffin, W. S. (1997). Glial-neuronal interactions in Alzheimer disease: Progressive association of IL-1alpha+ microglia and S100beta+ astrocytes with neurofibrillary tangle stages. Journal of Neuropathology and Experimental Neurology, 56, 285-290. (Pubitemid 27461169)
335. Shi, Q., & Gibson, G. E. (2007). Oxidative stress and transcriptional regulation in Alzheimer disease. Alzheimer Disease and Associated Disorders, 21, 276-291. (Pubitemid 350307432)
336. Shibata, N., Ohnuma, T., Higashi, S., Usui, C., Ohkubo, T., Kitajima, A., et al. (2005). Genetic association between matrix metalloproteinase MMP-9 and MMP-3 polymorphisms and Japanese sporadic Alzheimer's disease. Neurobiology of Aging, 26, 1011-1014. (Pubitemid 40312664)
337. Shimohama, S., Kamiya, S., Taniguchi, T., & Kimura, J. (1998). Intracellular receptors for activated C-kinase in the postmortem human brain: No alteration in Alzheimer disease. Alzheimer Disease and Associated Disorders, 12, 384-386. (Pubitemid 29050756)
338. Simakova, O., & Arispe, N. J. (2011). Fluorescent analysis of the cell-selective Alzheimer's disease Abeta peptide surface membrane binding: Influence of membrane components. International Journal of Alzheimer's Disease. doi:10.4061/2011/917629.
339. Simpson, I. A., Carruthers, A., & Vannucci, S. J. (2007). Supply and demand in cerebral energy metabolism: The role of nutrient transporters. Journal of Cerebral Blood Flow and Metabolism, 27, 1766-1791. (Pubitemid 47624552)
340. Simpson, J. E., Ince, P. G., Haynes, L. J., Theaker, R., Gelsthorpe, C., Baxter, L., et al. (2010a). Population variation in oxidative stress and astrocyte DNA damage in relation to Alzheimer-type pathology in the ageing brain. Neuropathology and Applied Neurobiology, 36, 25-40.
341. Simpson, J. E., Ince, P. G., Lace, G., Forster, G., Shaw, P. J., Matthews, F., et al. (2010b). Astrocyte phenotype in relation to Alzheimer-type pathology in the ageing brain. Neurobiology of Aging, 31, 578-590.
342. Singh, M., Nam, D. T., Arseneault, M., & Ramassamy, C. (2010). Role of by-products of lipid oxidation in Alzheimer's disease brain: A focus on acrolein. Journal of Alzheimer's Disease, 21, 741-756.
343. Sisodia, S. S., & Price, D. L. (1995). Role of the beta-amyloid protein in Alzheimer's disease. FASEB J, 9, 366-370.
344. Sklavounou-Andrikopoulou, A., Chrysomali, E., Iakovou, M., Garinis, G. A., & Karameris, A. (2004). Elevated serum levels of the apoptosis related molecules TNF-alpha, Fas/Apo-1 and Bcl-2 in oral lichen planus. Journal of Oral Pathology and Medicine, 33, 386-390. (Pubitemid 38988192)
345. Slater, A. F., Stefan, C., Nobel, I., van den Dobbelsteen, D. J., & Orrenius, S. (1995). Signalling mechanisms and oxidative stress in apoptosis. Toxicology Letters, 82-83, 149-153. (Pubitemid 26054701)
346. Smith, D. G., Cappai, R., & Barnham, K. J. (2007). The redox chemistry of the Alzheimer's disease amyloid beta peptide. Biochimica et Biophysica Acta, 1768, 1976-1990. (Pubitemid 47125850)
347. Smith, M. A., Hirai, K., Hsiao, K., Pappolla, M. A., Harris, P. L., Siedlak, S. L., et al. (1998). Amyloid-beta deposition in Alzheimer transgenic mice is associated with oxidative stress. Journal of Neurochemistry, 70, 2212-2215. (Pubitemid 28207848)
348. Smith-Swintosky, V. L., & Mattson, M. P. (1994). Glutamate, beta-amyloid precursor proteins, and calcium mediated neurofibrillary degeneration. Journal of Neural Transmission. Supplementum, 44, 29-45. (Pubitemid 24372886)
349. Sokolova, A., Hill, M. D., Rahimi, F., Warden, L. A., Halliday, G. M., & Shepherd, C. E. (2009). Monocyte chemoattractant protein-1 plays a dominant role in the chronic inflammation observed in Alzheimer's disease. Brain Pathology, 19, 392-398.
350. Spalletta, G., Bernardini, S., Bellincampi, L., Federici, G., Trequattrini, A., Ciappi, F., et al. (2007). Glutathione S-transferase P1 and T1 gene polymorphisms predict longitudinal course and age at onset of Alzheimer disease. The American Journal of Geriatric Psychiatry, 15, 879-887.
351. Squier, T. C. (2001). Oxidative stress and protein aggregation during biological aging. Experimental Gerontology, 36, 1539-1550. (Pubitemid 32768730)
352. Srikanth, V., Maczurek, A., Phan, T., Steele, M., Westcott, B., Juskiw, D., et al. (2011). Advanced glycation endproducts and their receptor RAGE in Alzheimer's disease. Neurobiology of Aging, 32, 763-777.
353. Standridge, J. B. (2006). Vicious cycles within the neuropathophysiologic mechanisms of Alzheimer's disease. Current Alzheimer Research, 3, 95-108.
354. Stanley, L. C., Mrak, R. E., Woody, R. C., Perrot, L. J., Zhang, S., Marshak, D. R., et al. (1994). Glial cytokines as neuropathogenic factors in HIV infection: Pathogenic similarities to Alzheimer's disease. Journal of Neuropathology and Experimental Neurology, 53, 231-238. (Pubitemid 24146860)
355. Streit, W. J., Conde, J. R., & Harrison, J. K. (2001). Chemokines and Alzheimer's disease. Neurobiology of Aging, 22, 909-913. (Pubitemid 34066558)
356. Strongin, A. Y. (2010). Proteolytic and non-proteolytic roles of membrane type-1 matrix metalloproteinase in malignancy. Biochimica et Biophysica Acta, 1803, 133-141.
357. Sultana, R., & Butterfield, D. A. (2008). Alterations of some membrane transport proteins in Alzheimer's disease: Role of amyloid beta-peptide. Molecular BioSystems, 4, 36-41.
358. Sultana, R., & Butterfield, D. A. (2009). Oxidatively modified, mitochondria-relevant brain proteins in subjects with Alzheimer disease and mild cognitive impairment. Journal of Bioenergetics and Biomembranes, 41, 441-446.
359. Sultana, R., Newman, S., Mohmmad-Abdul, H., Keller, J. N., & Butterfield, D. A. (2004). Protective effect of the xanthate, D609, on Alzheimer's amyloid beta-peptide (1-42)-induced oxidative stress in primary neuronal cells. Free Radical Research, 38, 449-458. (Pubitemid 38618366)
360. Sultana, R., Poon, H. F., Cai, J., Pierce, W. M., Merchant, M., Klein, J. B., et al. (2006). Identification of nitrated proteins in Alzheimer's disease brain using a redox proteomics approach. Neurobiology of Diseases, 22, 76-87.
361. Sun, Y. X., Minthon, L., Wallmark, A., Warkentin, S., Blennow, K., & Janciauskiene, S. (2003). Inflammatory markers in matched plasma and cerebrospinal fluid from patients with Alzheimer's disease. Dementia and Geriatric Cognitive Disorders, 16, 136-144. (Pubitemid 36736999)
362. Sung, S., Yang, H., Uryu, K., Lee, E. B., Zhao, L., Shineman, D., et al. (2004). Modulation of nuclear factor-kappa B activity by indomethacin influences A beta levels but not A beta precursor protein metabolism in a model of Alzheimer's disease. American Journal of Pathology, 165, 2197-2206. (Pubitemid 39578396)
363. Szczepanik, A. M., Funes, S., Petko, W., & Ringheim, G. E. (2001a). IL-4, IL-10 and IL-13 modulate A beta(1-42)-induced cytokine and chemokine production in primary murine microglia and a human monocyte cell line. Journal of Neuroimmunology, 113, 49-62. (Pubitemid 32008670)
364. Szczepanik, A. M., Rampe, D., & Ringheim, G. E. (2001b). Amyloidbeta peptide fragments p3 and p4 induce pro-inflammatory cytokine and chemokine production in vitro and in vivo. Journal of Neurochemistry, 77, 304-317. (Pubitemid 32245104)
365. Tamagno, E., Guglielmotto, M., Aragno, M., Borghi, R., Autelli, R., Giliberto, L., et al. (2008). Oxidative stress activates a positive feedback between the gamma- and beta-secretase cleavages of the beta-amyloid precursor protein. Journal of Neurochemistry, 104, 683-695.
366. Tamagno, E., Parola, M., Guglielmotto, M., Santoro, G., Bardini, P., Marra, L., et al. (2003). Multiple signaling events in amyloid beta-induced, oxidative stress-dependent neuronal apoptosis. Free Radical Biology and Medicine, 35, 45-58. (Pubitemid 36782336)
367. Tang, B. L. (2009). Neuronal protein trafficking associated with Alzheimer disease: From APP and BACE1 to glutamate receptors. Cell Adhesion & Migration, 3, 118-128.
368. Tarkowski, E., Blennow, K., Wallin, A., & Tarkowski, A. (1999). Intracerebral production of tumor necrosis factor-alpha, a local neuroprotective agent, in Alzheimer disease and vascular dementia. Journal of Clinical Immunology, 19, 223-230. (Pubitemid 29409451)
369. Terai, K., Matsuo, A., & McGeer, P. L. (1996). Enhancement of immunoreactivity for NF-kappa B in the hippocampal formation and cerebral cortex of Alzheimer's disease. Brain Research, 735, 159-168. (Pubitemid 26336632)
370. Thirumangalakudi, L., Samany, P. G., Owoso, A., Wiskar, B., & Grammas, P. (2006). Angiogenic proteins are expressed by brain blood vessels in Alzheimer's disease. Journal of Alzheimer's Disease, 10, 111-118. (Pubitemid 44401371)
371. Tibolla, G., Norata, G. D., Meda, C., Arnaboldi, L., Uboldi, P., Piazza, F., et al. (2010). Increased atherosclerosis and vascular inflammation in APP transgenic mice with apolipoprotein E deficiency. Atherosclerosis, 210, 78-87.
372. Tilleux, S., & Hermans, E. (2007). Neuroinflammation and regulation of glial glutamate uptake in neurological disorders. Journal of Neuroscience Research, 85, 2059-2070. (Pubitemid 47172138)
373. Tombaccini, D., Mocali, A., & Paoletti, F. (1994). Characteristic transketolase alterations in dermal fibroblasts of Alzheimer patients are modulated by culture conditions. Experimental and Molecular Pathology, 60, 140-146. (Pubitemid 24287210)
374. Tripathy, D., Thirumangalakudi, L., & Grammas, P. (2007). Expression of macrophage inflammatory protein 1-alpha is elevated in Alzheimer's vessels and is regulated by oxidative stress. Journal of Alzheimer's Disease, 11, 447-455. (Pubitemid 47094015)
375. Uematsu, Y., Hirano, A., Kawano, H., & Llena, J. F. (1989). The astrocyte-endothelial interface in cerebellar astrocytoma. No Shinkei Geka, 17, 999-1004. (Pubitemid 19279598)
376. Vassar, R. (2002). Beta-secretase (BACE) as a drug target for Alzheimer's disease. Advanced Drug Delivery Reviews, 54, 1589-1602. (Pubitemid 35346833)
377. Vassar, R. (2004). BACE1: The beta-secretase enzyme in Alzheimer's disease. Journal of Molecular Neuroscience, 23, 105-114.
378. Vassar, R., Bennett, B. D., Babu-Khan, S., Kahn, S., Mendiaz, E. A., Denis, P., et al. (1999). Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science, 286, 735-741.
379. 2, caspase-3, NF-kappaB, p53 and c-Jun. Neurotoxicology, 23, 351-365.
380. Venugopal, C., Demos, C. M., Rao, K. S., Pappolla, M. A., & Sambamurti, K. (2008). Beta-secretase: Structure, function, and evolution. CNS & Neurological Disorders Drug Targets, 7, 278-294.
381. Volicer, L., & Crino, P. B. (1990). Involvement of free radicals in dementia of the Alzheimer type: A hypothesis. Neurobiology of Aging, 11, 567-571. (Pubitemid 20297151)
382. Wan, L., Nie, G., Zhang, J., Luo, Y., Zhang, P., Zhang, Z., et al. (2011). Beta-amyloid peptide increases levels of iron content and oxidative stress in human cell and Caenorhabditis elegans models of Alzheimer disease. Free Radical Biology and Medicine, 50, 122-129.
383. Wang, M., & Jia, J. (2010). The interleukin-6 gene-572C/G promoter polymorphism modifies Alzheimer's risk in APOE epsilon 4 carriers. Neuroscience Letters, 482, 260-263.
384. White, A. R., Du, T., Laughton, K. M., Volitakis, I., Sharples, R. A., Xilinas, M. E., et al. (2006). Degradation of the Alzheimer disease amyloid beta-peptide by metal-dependent up-regulation of metalloprotease activity. The Journal of Biological Chemistry, 281, 17670-17680. (Pubitemid 44035565)
385. Whitson, J. S., & Appel, S. H. (1995). Neurotoxicity of A beta amyloid protein in vitro is not altered by calcium channel blockade. Neurobiology of Aging, 16, 5-10.
386. Williams, K., Ulvestad, E., Waage, A., Antel, J. P., & McLaurin, J. (1994). Activation of adult human derived microglia by myelin phagocytosis in vitro. Journal of Neuroscience Research, 38, 433-443. (Pubitemid 24209433)
387. Wilson, R. S., Weir, D. R., Leurgans, S. E., Evans, D. A., Hebert, L. E., Langa, K. M., et al. (2011). Sources of variability in estimates of the prevalence of Alzheimer's disease in the United States. Alzheimers Dementia, 7, 74-79.
388. Wong, A., Luth, H. J., Deuther-Conrad, W., Dukic-Stefanovic, S., Gasic-Milenkovic, J., Arendt, T., et al. (2001). Advanced glycation endproducts co-localize with inducible nitric oxide synthase in Alzheimer's disease. Brain Research, 920, 32-40. (Pubitemid 33086777)
389. Woodle, E. S., & Kulkarni, S. (1998). Programmed cell death. Transplantation, 66, 681-691. (Pubitemid 28460101)
390. Wyss-Coray, T. (2006). Inflammation in Alzheimer disease: Driving force, bystander or beneficial response? Nature Medicine, 12, 1005-1015. (Pubitemid 44353380)
391. Xia, M. Q., & Hyman, B. T. (1999). Chemokines/chemokine receptors in the central nervous system and Alzheimer's disease. Journal of Neurovirology, 5, 32-41. (Pubitemid 29051876)
392. Xia, M. Q., Qin, S. X., Wu, L. J., Mackay, C. R., & Hyman, B. T. (1998). Immunohistochemical study of the beta-chemokine receptors CCR3 and CCR5 and their ligands in normal and Alzheimer's disease brains. American Journal of Pathology, 153, 31-37. (Pubitemid 28317504)
393. Yamamoto, M., Kiyota, T., Horiba, M., Buescher, J. L., Walsh, S. M., Gendelman, H. E., et al. (2007). Interferon-gamma and tumor necrosis factor-alpha regulate amyloid-beta plaque deposition and beta-secretase expression in Swedish mutant APP transgenic mice. American Journal of Pathology, 170, 680-692. (Pubitemid 47339404)
394. Yan, S. D., Bierhaus, A., Nawroth, P. P., & Stern, D. M. (2009). RAGE and Alzheimer's disease: A progression factor for amyloid-beta-induced cellular perturbation? Journal of Alzheimer's Disease, 16, 833-843.
395. Yan, J. J., Cho, J. Y., Kim, H. S., Kim, K. L., Jung, J. S., Huh, S. O., et al. (2001). Protection against beta-amyloid peptide toxicity in vivo with long-term administration of ferulic acid. British Journal of Pharmacology, 133, 89-96.
396. Yan, F. L., Zheng, Y., & Zhao, F. D. (2008). Effects of ginkgo biloba extract EGb761 on expression of RAGE and LRP-1 in cerebral microvascular endothelial cells under chronic hypoxia and hypoglycemia. Acta Neuropathologica, 116, 529-535.
397. Yang, Y., Quitschke, W. W., & Brewer, G. J. (1998a). Upregulation of amyloid precursor protein gene promoter in rat primary hippocampal neurons by phorbol ester, IL-1 and retinoic acid, but not by reactive oxygen species. Brain Research. Molecular Brain Research, 60, 40-49. (Pubitemid 28433193)
398. Yang, F., Sun, X., Beech, W., Teter, B., Wu, S., Sigel, J., et al. (1998b). Antibody to caspase-cleaved actin detects apoptosis in differentiated neuroblastoma and plaque-associated neurons and microglia in Alzheimer's disease. American Journal of Pathology, 152, 379-389. (Pubitemid 28106384)
399. Yao, Y., Chinnici, C., Tang, H., Trojanowski, J. Q., Lee, V. M., & Pratico, D. (2004). Brain inflammation and oxidative stress in a transgenic mouse model of Alzheimer-like brain amyloidosis. Journal of Neuroinflammation, 1, 21.
400. Yatin, S. M., Varadarajan, S., Link, C. D., & Butterfield, D. A. (1999). In vitro and in vivo oxidative stress associated with Alzheimer's amyloid beta-peptide (1-42). Neurobiology of Aging, 20, 325-330 (discussion 339-342). (Pubitemid 29525418)
401. Yoshiyama, Y., Asahina, M., & Hattori, T. (2000). Selective distribution of matrix metalloproteinase-3 (MMP-3) in Alzheimer's disease brain. Acta Neuropathologica, 99, 91-95. (Pubitemid 30093413)
402. Yu, W., Mechawar, N., Krantic, S., & Quirion, R. (2010). Evidence for the involvement of apoptosis-inducing factor-mediated caspase-independent neuronal death in Alzheimer disease. American Journal of Pathology, 176, 2209-2218.
403. Zhang, L., Bukulin, M., Kojro, E., Roth, A., Metz, V. V., Fahrenholz, F., et al. (2008). Receptor for advanced glycation end products is subjected to protein ectodomain shedding by metalloproteinases. The Journal of Biological Chemistry, 283, 35507-35516.
404. Zhang, X., Luhrs, K. J., Ryff, K. A., Malik, W. T., Driscoll, M. J., & Culver, B. (2009). Suppression of nuclear factor kappa B ameliorates astrogliosis but not amyloid burden in APPswe/PS1dE9 mice. Neuroscience, 161, 53-58.
405. Zhang, M., Mao, Y., Ramirez, S. H., Tuma, R. F., & Chabrashvili, T. (2010). Angiotensin II induced cerebral microvascular inflammation and increased blood-brain barrier permeability via oxidative stress. Neuroscience, 171, 852-858.
406. Zhang, Y., Xu, J., Levin, J., Hegen, M., Li, G., Robertshaw, H., et al. (2004). Identification and characterization of 4-[[4-(2-butynyloxy)phenyl] sulfonyl]-N-hydroxy-2,2-dimethyl-(3S)thiomorpho linecarboxamide (TMI-1), a novel dual tumor necrosis factor-alpha-converting enzyme/matrix metalloprotease inhibitor for the treatment of rheumatoid arthritis. Journal of Pharmacology and Experimental Therapeutics, 309, 348-355. (Pubitemid 38393148)
407. Zhao, M., Cribbs, D. H., Anderson, A. J., Cummings, B. J., Su, J. H., Wasserman, A. J., et al. (2003). The induction of the TNFalpha death domain signaling pathway in Alzheimer's disease brain. Neurochemical Research, 28, 307-318. (Pubitemid 36207354)
408. Zhou, D., Lauderback, C. M., Yu, T., Brown, S. A., Butterfield, D. A., & Thompson, J. S. (2001). D609 inhibits ionizing radiationinduced oxidative damage by acting as a potent antioxidant. Journal of Pharmacology and Experimental Therapeutics, 298, 103-109. (Pubitemid 32574515)
409. Zhu, W., Mix, E., & Zhu, J. (2003). Inflammation and proinflammatory cytokine production, but no demyelination of facial nerves, in experimental autoimmune neuritis in Lewis rats. Journal of Neuroimmunology, 140, 97-101. (Pubitemid 36836094)
410. Zlokovic, B. V., Deane, R., Sagare, A. P., Bell, R. D., & Winkler, E. A. (2010). Low-density lipoprotein receptor-related protein-1: A serial clearance homeostatic mechanism controlling Alzheimer's amyloid beta-peptide elimination from the brain. Journal of Neurochemistry, 115, 1077-1089.
411. Zouambia, M., Fischer, D. F., Hobo, B., De Vos, R. A., Hol, E. M., Varndell, I. M., et al. (2008). Proteasome subunit proteins and neuropathology in tauopathies and synucleinopathies: Consequences for proteomic analyses. Proteomics, 8, 1221-1236. (Pubitemid 351462928)